<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Cellular and Infection Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Infect. Microbiol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2235-2988</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcimb.2026.1763669</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Essential role of cytochrome <italic>bc</italic><sub>1</sub> in <italic>Pseudomonas aeruginosa</italic> cell physiology and virulence</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Sorescu</surname><given-names>Jennifer M.</given-names></name>
<uri xlink:href="https://loop.frontiersin.org/people/3369756/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Gonz&#xe1;lez-Montalvo</surname><given-names>Mart&#xed;n A.</given-names></name>
<uri xlink:href="https://loop.frontiersin.org/people/335674/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Patel</surname><given-names>Nancy</given-names></name>
<uri xlink:href="https://loop.frontiersin.org/people/3366238/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Baltes</surname><given-names>Gabriella</given-names></name>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Avula</surname><given-names>Shriya R.</given-names></name>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Tuz</surname><given-names>Karina</given-names></name>
<uri xlink:href="https://loop.frontiersin.org/people/1974949/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ju&#xe1;rez</surname><given-names>Oscar X.</given-names></name>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/630715/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
</contrib>
</contrib-group>
<aff id="aff1"><institution>Department of Biological Sciences, Illinois Institute of Technology</institution>, <city>Chicago</city>, <state>IL</state>, <country country="us">United States</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Oscar X. Ju&#xe1;rez, <email xlink:href="mailto:ojuarez@illinoistech.edu">ojuarez@illinoistech.edu</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-25">
<day>25</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>16</volume>
<elocation-id>1763669</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>02</month>
<year>2026</year>
</date>
<date date-type="rev-recd">
<day>26</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Sorescu, Gonz&#xe1;lez-Montalvo, Patel, Baltes, Avula, Tuz and Ju&#xe1;rez.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Sorescu, Gonz&#xe1;lez-Montalvo, Patel, Baltes, Avula, Tuz and Ju&#xe1;rez</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-25">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p><italic>Pseudomonas aeruginosa</italic> is a multidrug-resistant Gram-negative nosocomial pathogen posing a major healthcare burden due to its intrinsic antibiotic resistance and environmental adaptability, which continue to significantly constrain therapeutic options. This pathogen is a leading cause of hospital-acquired respiratory and urinary tract infections that are often persistent and difficult to treat. The elucidation of metabolic adaptations permitting <italic>P. aeruginosa</italic> survival and supporting virulence in diverse host environments is essential for informing novel treatments. This study investigates the role of cytochrome <italic>bc</italic><sub>1</sub> in <italic>P. aeruginosa</italic> PA14 growth, energetics, and virulence <italic>in vitro</italic>, under physiologically relevant conditions, and <italic>in vivo</italic>. The <italic>bc</italic><sub>1</sub> deletion mutant exhibits significant growth defects in urinary- and lung-like media, demonstrating its importance in PA14 physiology, and displays reduced virulence in bladder epithelial cell monolayers, mediated by decreased type III secretion system (T3SS) toxin expression. <italic>In vivo</italic>, the mutant was nearly avirulent in a murine systemic infection model. Bioenergetic analysis revealed severe decline in PA14 &#x394;<italic>bc</italic><sub>1</sub> ATP production, aligning with the enzyme&#x2019;s central role in respiration and providing a mechanistic explanation for the mutant&#x2019;s reduced T3SS function, as toxin secretion requires energy. This work provides compelling evidence of direct T3SS regulation by cytochrome <italic>bc</italic><sub>1</sub>, revealing a previously unrecognized link between respiratory metabolism and virulence. Metabolic profiling indicates that to compensate for cytochrome <italic>bc</italic><sub>1</sub> loss, the mutant relies on NDH-2 and <italic>bd</italic> oxidase, permitting cellular survival but substantially reducing ATP yield. Collectively, these findings establish cytochrome <italic>bc</italic><sub>1</sub> as a target for antibiotic development against <italic>P. aeruginosa</italic>, impacting bioenergetics, physiology, and virulence.</p>
</abstract>
<kwd-group>
<kwd>antibiotic resistance</kwd>
<kwd>antibiotics</kwd>
<kwd>cytochrome <italic>bc</italic><sub>1</sub></kwd>
<kwd>electron transport</kwd>
<kwd><italic>Pseudomonas aeruginosa</italic></kwd>
<kwd>respiratory chain</kwd>
<kwd>type III secretion system (T3SS)</kwd>
<kwd>virulence factor</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">
<institution-wrap>
<institution>National Institutes of Health</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This work was funded by NIH-NIAID 1R01AI151152-01A1 to OJ and KT. JMS was partially funded by the Pritzker Institute, Illinois Institute of Technology. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="104"/>
<page-count count="16"/>
<word-count count="10537"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Molecular Bacterial Pathogenesis</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Multidrug-resistant <italic>Pseudomonas aeruginosa</italic> is an opportunistic pathogen that poses a serious threat to human health due to its prevalence and lack of effective therapeutic treatments. In 2019, <italic>P. aeruginosa</italic> was the sixth leading global pathogen in deaths associated with antimicrobial resistance (<xref ref-type="bibr" rid="B69">Murray et&#xa0;al., 2022</xref>). This problem has become more challenging, as multidrug-resistant <italic>P. aeruginosa</italic> infections in hospital-onset cases increased &gt;30% in only two years (2019-2020) (<xref ref-type="bibr" rid="B6">COVID-19 Special Report, 2022</xref>). The World Health Organization (WHO) designated carbapenem-resistant <italic>P. aeruginosa</italic> as a high priority pathogen, emphasizing the urgent need for development of new antibiotics against this bacterium (<xref ref-type="bibr" rid="B8">WHO Bacterial Priority Pathogens List 2024, 2024</xref>). <italic>P. aeruginosa</italic> accounts for approximately 23% of ICU-acquired infections worldwide and 7% of healthcare-associated infections in the U.S., causing acute and chronic infections in immunocompromised patients, particularly those suffering from respiratory diseases and urinary tract infections (UTIs) (<xref ref-type="bibr" rid="B80">Qin et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B82">Reynolds and Kollef, 2021</xref>). <italic>P. aeruginosa</italic> is responsible for 7-10% of all UTIs and 10% of catheter-associated UTIs (CAUTIs) (<xref ref-type="bibr" rid="B62">Mancuso et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B82">Reynolds and Kollef, 2021</xref>). Although uropathogenic <italic>Escherichia coli</italic> has a higher prevalence (65%) among nosocomial UTIs (<xref ref-type="bibr" rid="B62">Mancuso et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B71">Newman et&#xa0;al., 2022</xref>), infections caused by <italic>P. aeruginosa</italic> are considerably more difficult to treat due to their increased propensity for antibiotic resistance. Approximately 10% of <italic>P. aeruginosa</italic> isolates from healthcare settings are multidrug-resistant, with over 10% of CAUTIs caused by multidrug-resistant (MDR) strains (<xref ref-type="bibr" rid="B7">Multidrug-resistant Pseudomonas aeruginosa, 2022</xref>). Moreover, <italic>P. aeruginosa</italic> is the second most prevalent cause of ventilator-associated pneumonia, responsible for 26% of cases globally (<xref ref-type="bibr" rid="B82">Reynolds and Kollef, 2021</xref>). Additionally, <italic>P. aeruginosa</italic> is the predominant pathogen in chronic cystic fibrosis (CF) cases, found in 40-50% of adult cases (<xref ref-type="bibr" rid="B72">Nickerson et&#xa0;al., 2024</xref>), which increases morbidity and mortality (<xref ref-type="bibr" rid="B17">Chmiel and Davis, 2003</xref>; <xref ref-type="bibr" rid="B47">Kamal et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B61">Lyczak et&#xa0;al., 2000</xref>). Similarly, the chronic presence of <italic>P. aeruginosa</italic> in respiratory secretions is a major predictor of morbidity and mortality in children with CF (<xref ref-type="bibr" rid="B83">Rosenfeld et&#xa0;al., 2001</xref>). Chronic colonization of the respiratory tract fosters an increase in mutations, adaptations, and persistence that contribute to treatment resistance (<xref ref-type="bibr" rid="B68">Moradali et&#xa0;al., 2017</xref>). It is evident that the development of novel antibiotics is critical to reduce the impact of this pathogen on global healthcare outcomes. <italic>P. aeruginosa</italic> infections are treated with antibiotics such as penicillins, cephalosporins, fluoroquinolones, aminoglycosides, or carbapenems (<xref ref-type="bibr" rid="B52">Kunz Coyne et&#xa0;al., 2022</xref>). However, <italic>P. aeruginosa</italic> produces drug-tolerant persister cells that are prevalent in biofilms (<xref ref-type="bibr" rid="B70">Narten et&#xa0;al., 2012</xref>; <xref ref-type="bibr" rid="B18">Ciofu et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B91">Soares et&#xa0;al., 2020</xref>), which reduce treatment efficacy and give rise to MDR, extensively drug-resistant (XDR), or pan drug-resistant (PDR) infections (<xref ref-type="bibr" rid="B25">Eid et&#xa0;al., 2025</xref>). There are limited therapeutic options for managing such infections, and inappropriate initial treatment or delays in administering effective therapy often result in treatment failure (<xref ref-type="bibr" rid="B11">Bassetti et&#xa0;al., 2020</xref>). Thus, there is an urgent need for identification of novel antibiotic targets that can be exploited against <italic>P. aeruginosa</italic>.</p>
<p>The respiratory chain of <italic>P. aeruginosa</italic> is highly branched, allowing adaptation to a multitude of environments due to its unique flexibility (<xref ref-type="bibr" rid="B94">Stover et&#xa0;al., 2000</xref>; <xref ref-type="bibr" rid="B100">Williams et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B65">Mikkelsen et&#xa0;al., 2011</xref>). In aerobic conditions, the bacterium primarily relies on oxidative phosphorylation to drive ATP production (<xref ref-type="bibr" rid="B100">Williams et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B2">Alvarez-Ortega and Harwood, 2007</xref>; <xref ref-type="bibr" rid="B3">Arai, 2011</xref>) rather than fermentation (<xref ref-type="bibr" rid="B100">Williams et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B3">Arai, 2011</xref>; <xref ref-type="bibr" rid="B54">La Rosa et&#xa0;al., 2018</xref>, <xref ref-type="bibr" rid="B55">2019</xref>; <xref ref-type="bibr" rid="B2">Alvarez-Ortega and Harwood, 2007</xref>), utilizing 17 dehydrogenases (<xref ref-type="bibr" rid="B94">Stover et&#xa0;al., 2000</xref>) that facilitate electron transfer to either ubiquinone, nitrate reductases, or cytochrome <italic>c</italic> (<xref ref-type="bibr" rid="B94">Stover et&#xa0;al., 2000</xref>; <xref ref-type="bibr" rid="B100">Williams et&#xa0;al., 2007</xref>). Electrons are subsequently funneled to oxygen from quinol via cytochrome <italic>bo</italic><sub>3</sub> oxidase, cyanide-insensitive <italic>bd</italic>-like oxidase, or cytochrome <italic>bc</italic><sub>1</sub> and cytochrome <italic>c</italic> oxidases (<xref ref-type="bibr" rid="B3">Arai, 2011</xref>; <xref ref-type="bibr" rid="B29">Giuffr&#xe8; et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B94">Stover et&#xa0;al., 2000</xref>; <xref ref-type="bibr" rid="B100">Williams et&#xa0;al., 2007</xref>). Our group previously investigated the respiratory metabolism of <italic>P. aeruginosa</italic> in urine-like conditions (<xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>). We reported that cytochrome <italic>bc</italic><sub>1</sub> is a main component of the pathogen&#x2019;s respiratory chain in both logarithmic and stationary growth phases, accounting for 50-60% of the respiratory activity (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>), indicating that this could be an important pharmacological target. Cytochrome <italic>bc</italic><sub>1</sub> has been effectively exploited as a therapeutic target in parasitic and fungal pathogens by the FDA-approved drug atovaquone, underscoring substantial structural divergence between pathogenic and mammalian complexes and supporting its viability as an effective and selective drug target (<xref ref-type="bibr" rid="B9">Baggish and Hill, 2002</xref>; <xref ref-type="bibr" rid="B98">Walker et&#xa0;al., 1998</xref>).</p>
<p>Given the clinical importance of <italic>P. aeruginosa</italic> and the growing need for novel antimicrobial strategies, we sought to explore the functional role of cytochrome <italic>bc</italic><sub>1</sub> in the reference strain PA14, a highly virulent strain isolated from a burn wound (<xref ref-type="bibr" rid="B37">He et&#xa0;al., 2004</xref>; <xref ref-type="bibr" rid="B99">Wiehlmann et&#xa0;al., 2007</xref>), characterizing the role of this critical enzyme in bacterial bioenergetics, homeostasis, and virulence. Our data show that the deletion of cytochrome <italic>bc</italic><sub>1</sub> produced significant defects in bacterial proliferation in LB and the physiologically relevant modified artificial urinary medium (mAUM) and lung medium (LM). Moreover, the mutant exhibited reduced virulence in an <italic>in vitro</italic> infection model of human bladder cells, which was due to a decrease in the expression of the type 3 secretion system (T3SS), and was reflected in an almost completely avirulent phenotype in a murine model. A significant reduction in ATP production was observed in the mutant during logarithmic and stationary growth phases across all media tested, which provides a direct link to the diminished function of the T3SS, driven by ATP hydrolysis. Analysis of the metabolic adaptations the pathogen undergoes to compensate for loss of the enzyme indicates a reliance on the type-2 NADH dehydrogenase (NDH-2) and the cyanide-insensitive <italic>bd</italic> oxidase, which allows the bacteria to survive the elimination of this critical enzyme, but significantly decreases its ability to produce ATP and, consequently, to cause disease. These findings validate cytochrome <italic>bc</italic><sub>1</sub> as a pharmacological target with significant potential for therapeutic development against <italic>P. aeruginosa</italic>.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="s2_1">
<title>Mutant construction</title>
<p>To generate the PA14 &#x394;<italic>bc</italic><sub>1</sub> mutant, a lambda-red recombinase method was used (<xref ref-type="bibr" rid="B15">Bru et&#xa0;al., 2019</xref>; <xref ref-type="bibr" rid="B22">Datsenko and Wanner, 2000</xref>). <italic>P. aeruginosa</italic> PA14 cells were transformed with pUCP18-RedS as previously described (<xref ref-type="bibr" rid="B57">Lesic and Rahme, 2008</xref>) and selected in LB medium + carbenicillin 300 &#xb5;g/mL. The lambda-red system in cells harboring pUCP18-RedS was induced with 10 mM arabinose. Cells were pelleted at 16,000 &#xd7; <italic>g</italic> for 10 minutes at room temperature and were washed with 300 mM sucrose. Electrocompetent cells were transformed with the mutagenic amplicon into pUCP18-RedS-positive cells in a 0.4 cm gap cuvette at 2500 V using a MicroPulser Electroporator (Bio-Rad, Hercules, CA) as previously reported (<xref ref-type="bibr" rid="B15">Bru et&#xa0;al., 2019</xref>). For the mutagenic amplicon, regions of 500&#x2013;650 bp upstream and downstream of the operon encoding cytochrome <italic>bc</italic><sub>1</sub> (<italic>petA</italic>-<italic>cytB</italic>-<italic>cytC</italic><sub>1</sub>) were amplified using the primer pairs listed in <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>. The gentamicin cassette of pAS03 was amplified using the primers Gm_pAS03_F and Gm_pAS03_R (<xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>). The three amplicons were combined and amplified via fusion PCR using the <italic>Bc</italic><sub>1</sub> Upstream Bc1_Mut_F and <italic>Bc</italic><sub>1</sub> Downstream Bc1_Mut_R primers. Mutants were selected on gentamicin plates (30 &#xb5;g/mL) and verified by PCR using the primers Bc1_F and Bc1_R and by nanopore bacterial genomic sequencing (Eurofins Genomics, Louisville, KY). Our sequencing data show a single elimination of the <italic>bc</italic><sub>1</sub> operon with no insertions or deletions in any other site. The genome sequence of the mutant is available upon request.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Primers for mutant construction.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Primer pair</th>
<th valign="middle" align="center">Primer</th>
<th valign="middle" align="center">Sequence (5&#x2019;-3&#x2019;)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" rowspan="2" align="center">Gm cassette</td>
<td valign="top" align="center">Gm_pAS03_F</td>
<td valign="top" align="left">TGTGTAGGCTGGAGCTGCTTCGAAG</td>
</tr>
<tr>
<td valign="top" align="center">Gm_pAS03_R</td>
<td valign="top" align="left">ATTCCGGGGATCCGTCG</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="center"><italic>Bc</italic><sub>1</sub> Upstream</td>
<td valign="top" align="center">Bc1_Mut_F</td>
<td valign="top" align="left">CGTGCCCTGATCGAGTACGAC</td>
</tr>
<tr>
<td valign="top" align="center">Bc1_Mut_R</td>
<td valign="top" align="left">CCAGCTGCCTAGGGGCCTTTCTTGCCCACGTTCACCTGCAC</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="center"><italic>Bc</italic><sub>1</sub> Downstream</td>
<td valign="top" align="center">Bc1_Mut_F</td>
<td valign="top" align="left">GAAGCAGCTCCAGCCTACACAATCTACGCCCGGGAAAACGGC</td>
</tr>
<tr>
<td valign="top" align="center">Bc1_Mut_R</td>
<td valign="top" align="left">CGCCAAGGCCGATCCAGCCC</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="center">Verification</td>
<td valign="top" align="center">Bc1_F</td>
<td valign="top" align="left">CTGACAGAGCTCGTAAAGGAGGAATTAACCATGAGTAATGACGGCG</td>
</tr>
<tr>
<td valign="top" align="center">Bc1_R</td>
<td valign="top" align="left">GTCACTCAGCTGTTACTTGACCACCTTCAGGGATGG</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2_2">
<title><italic>P. aeruginosa</italic> growth and analysis</title>
<p><italic>P. aeruginosa</italic> strains PA14 (wild-type) and PA14 &#x394;<italic>bc</italic><sub>1</sub> were grown in LB Broth (Miller), modified artificial urinary medium (mAUM), and lung medium (LM) at 37&#xb0;C with shaking at 250 RPM as reported previously (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>; <xref ref-type="bibr" rid="B84">Ruhluel et&#xa0;al., 2022</xref>). mAUM and LM were prepared as described previously (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>; <xref ref-type="bibr" rid="B84">Ruhluel et&#xa0;al., 2022</xref>). Growth was assessed by following the absorbance of cell cultures at 620 nm using an 800 TS microplate reader (BioTek, Winooski, VT). Maximum growth, duplication time, and lag phase duration were calculated by fitting the growth data to logistic functions, as previously detailed in our work (<xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>; <xref ref-type="bibr" rid="B46">Kahm et&#xa0;al., 2010</xref>). Experiments were conducted in triplicate, with results reported as mean &#xb1; SD, <italic>n</italic> = 3. Statistical significance between PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> was assessed using <italic>t</italic>-test analysis.</p>
</sec>
<sec id="s2_3">
<title>Human urinary bladder 5637 carcinoma cell infection assay</title>
<p>5637 human urinary bladder carcinoma cells (ATCC HTB-9) were cultured in RPMI 1640 medium supplemented with 10% Fetal Bovine Serum (FBS). Following treatment with 0.25% trypsin-EDTA, 2.0 x 10<sup>5</sup> cells were seeded in 24 well plates and incubated for 48 hours at 37 &#xb0;C with 5% CO<sub>2</sub> in a humidified atmosphere prior to infection. <italic>P. aeruginosa</italic> strains PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> were grown for 24 hours in LB at 37 &#xb0;C under continuous agitation (250 RPM). Bacterial cells were centrifuged at 16,000 &#xd7; <italic>g</italic> for 10 minutes at room temperature and washed with PBS. Monolayers of 5637 cells were washed with PBS, and fresh RPMI 1640 supplemented with 10% FBS was added. Bladder cells were then infected with PA14 or PA14 &#x394;<italic>bc</italic><sub>1</sub> at a MOI of 10 for 2, 4, and 6 hours. At each time point, cells were washed with PBS and stained with a 1:1 mixture of PBS:trypan blue (0.4%). Bright-field images were collected using a Keyence BZ-X710 Fluorescence Microscope (Itasca, IL) with a cooled monochrome CCD camera and Nikon Plan Fluor ELWD 20x/0.45 Ph1 ADM, &#x221e;/0&#x2013;2 WD 8.2&#x2013;6.9 lens. Quantification of cell viability post-infection was performed using the BZ-X analyzer (version 01.03.00.05) and ImageJ v1.54p (<xref ref-type="bibr" rid="B1">Abramoff et&#xa0;al., 2004</xref>), with assessors blinded to outcomes. Viability was quantified by calculating the percentage of live cells (unstained) from the total cells [unstained plus stained (dead)]. Results are reported as mean &#xb1; SD, <italic>n</italic> = 3, with statistical significance between PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> assessed via <italic>t</italic>-test.</p>
</sec>
<sec id="s2_4">
<title>Type III secretion system detection</title>
<p>Following 5637 cell infection with <italic>P. aeruginosa</italic> strains PA14 or PA14 &#x394;<italic>bc</italic><sub>1</sub>, expression of the type III secretion system (T3SS) proteins exoT, exoU, and exoY was assessed in the media of the infected cell culture at 4 hours post-infection (hpi). Supernatant total RNA was extracted using TRIzol LS (Thermo Fisher Scientific, Waltham, MA) and quantified on a Qubit 3.0 fluorometer using the AccuBlue Broad Range RNA Quantitation Kit (Biotium, Fremont, CA), followed by cDNA synthesis with the ProtoScript II First Strand cDNA Synthesis Kit using the Random Primer Mix (New England Biolabs, Ipswich, MA). qPCR was subsequently performed using the primer pairs listed in <xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref>, designed using Primer 3 software (<xref ref-type="bibr" rid="B50">Koressaar and Remm, 2007</xref>; <xref ref-type="bibr" rid="B97">Untergasser et&#xa0;al., 2012</xref>; <xref ref-type="bibr" rid="B49">K&#xf5;ressaar et&#xa0;al., 2018</xref>). <italic>P. aeruginosa rpoD</italic> was utilized as a housekeeping gene due to its vital role in promoter identification to facilitate constitutive gene expression (<xref ref-type="bibr" rid="B79">Potvin et&#xa0;al., 2008</xref>; <xref ref-type="bibr" rid="B86">Savli et&#xa0;al., 2003</xref>). cDNA (100 ng) amplification and quantification were performed on a Bio-Rad CFX Connect Real-Time PCR Detection System using the iTaq Universal SYBR Green Supermix kit (Bio-Rad, Hercules, CA). mRNA expression was determined via a 2-&#x394;&#x394;CT method comparing <italic>rpoD</italic>, <italic>exoT</italic>, <italic>exoU</italic>, and <italic>exoY</italic> expression in the presence of <italic>P. aeruginosa</italic> PA14 or PA14 &#x394;<italic>bc</italic><sub>1</sub> infection via cycle threshold analysis (<xref ref-type="bibr" rid="B60">Livak and Schmittgen, 2001</xref>). Data are presented as mean &#xb1; SE, <italic>n</italic> = 9, with statistical significance determined via <italic>t</italic>-test.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Primers for T3SS Detection.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="center">Target gene</th>
<th valign="middle" align="center">Sequence (5&#x2019;-3&#x2019;)</th>
<th valign="middle" align="center">Amplicon size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center"><italic>exoT</italic></td>
<td valign="middle" align="center">TGCATGCGGTAATGGACAAG<break/>GTATAGAGACCGAGCGCCAT</td>
<td valign="middle" align="right">190</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>exoU</italic></td>
<td valign="middle" align="center">CGTACTCTGACTGACTCGGC<break/>GCCTTTCTCTTCTAGCGCCA</td>
<td valign="middle" align="right">171</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>exoY</italic></td>
<td valign="middle" align="center">ATGACCGCCGATTATGACCT<break/>CTCCCTGCCATAGAATCCGT</td>
<td valign="middle" align="right">150</td>
</tr>
<tr>
<td valign="middle" align="center"><italic>rpoD</italic></td>
<td valign="middle" align="center">GCATCCTGGCCGACTACAAT TGCTGTCGTCGCTTTCTTCT</td>
<td valign="middle" align="right">183</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2_5">
<title>Mouse model of <italic>P. aeruginosa</italic> infection</title>
<p><italic>P. aeruginosa</italic> infection in mice was performed using a sepsis model, as described previously (<xref ref-type="bibr" rid="B90">Six et&#xa0;al., 2021</xref>). PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> were grown in LB medium for 24 hours, followed by centrifugation at 16,000 &#xd7; <italic>g</italic> for 10 minutes at room temperature. Cells were washed with PBS and eight-week-old female BALB/cJ mice (The Jackson Laboratory, Bar Harbor, ME) were inoculated with 50 &#xb5;l of PBS (<italic>n</italic> = 7), 1.25-1.64 x 10<sup>7</sup> CFUs of PA14 (<italic>n</italic> = 17), or 1.50-1.60 x 10<sup>7</sup> CFUs of PA14 &#x394;<italic>bc</italic><sub>1</sub> (<italic>n</italic> = 14) intravenously through lateral tail vein using a 29G syringe, according to Illinois Institute of Technology IACUC-approved protocols. Animals were provided with unrestricted access to food and water and kept on a standard 12 h light/dark cycle with lights off at 7:00 p.m. Animals&#x2019; weights and survival were monitored twice daily for one week post-infection. Survival outcomes were visualized with Kaplan-Meier curves and statistically evaluated using the log-rank test implemented in OriginLab (version Origin 2025b (10.25), OriginLab Corporation, Northampton, MA).</p>
</sec>
<sec id="s2_6">
<title>Biofilm determination</title>
<p>Biofilm formation was assessed for <italic>P. aeruginosa</italic> strains PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub>, as described previously (<xref ref-type="bibr" rid="B74">O&#x2019;Toole, 2011</xref>). Bacterial overnight cultures were grown in LB at 37 &#xb0;C with shaking (250 RPM). One milliliter of bacteria culture was centrifuged at 16,000 &#xd7; <italic>g</italic> for 10 minutes at room temperature, and cells were washed with PBS twice. Bacterial pellets were resuspended in 1 mL of PBS and adjusted to OD<sub>600</sub> of 1.0. This suspension was further diluted to an OD<sub>600</sub> of 0.01 in LB, mAUM, or LM. 100 uL of each suspension was transferred to individual wells of 96-well plates. Experiments were performed three times using 10 technical replicates per condition and strain. Plates were incubated at 37 &#xb0;C for 48 hours without shaking. Following incubation, supernatant was removed, and wells were washed three times with PBS and allowed to air dry. Biofilm was stained with 1% filtered crystal violet for 30 minutes, dye was removed, and wells were washed with ultrapure water. Retained crystal violet was solubilized with 33% acetic acid and absorbance was read at 595 nm using an 800 TS microplate reader (BioTek, Winooski, VT). Statistical significance between PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> was determined via <italic>t</italic>-test.</p>
</sec>
<sec id="s2_7">
<title>ATP quantification</title>
<p>ATP detection was performed using the BacTiter-Glo&#x2122; Microbial Cell Viability Assay (Promega, Madison, WI) according to manufacturer&#x2019;s instructions. Cultures of <italic>P. aeruginosa</italic> strains PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> harvested during both logarithmic and stationary phases following growth in LB, mAUM, and LM were vortexed and combined with BacTiter-Glo&#x2122; reagent in a 1:1 ratio in 96-well white opaque-walled plates. For cultures grown in LB, mAUM, and LM, logarithmic growth was defined at 7, 7, and 16 hours post-inoculation, respectively, whereas stationary phase was designated at 24, 12, and 24 hours for LB, mAUM, and LM, respectively. Culture reagent mixtures were incubated for five minutes and luminescence was recorded. ATP standard curves were prepared in LB, mAUM, and LM and obtained values were interpolated based on the appropriate media to obtain moles of ATP in each sample. Protein was quantified via BCA assay (Thermo Fisher Scientific, cat. no. 23225, Waltham, MA) and ATP quantity was subsequently normalized to protein concentration. Experiment was performed in triplicate, with results reported as mean &#xb1; SD, <italic>n</italic> = 3. Statistical significance between PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> was determined using a <italic>t</italic>-test.</p>
</sec>
<sec id="s2_8">
<title>Reactive oxygen species detection</title>
<p>ROS detection was carried out according to Fraser-Pitt et al. (<xref ref-type="bibr" rid="B28">Fraser-Pitt et&#xa0;al., 2018</xref>). <italic>P. aeruginosa</italic> strains PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> were grown in LB, mAUM, and LM at 37 &#xb0;C with shaking at 250 RPM and harvested in the logarithmic and stationary phases of growth. Samples were subsequently centrifuged at 16,000 &#xd7; <italic>g</italic> for 10 minutes and washed with PBS at room temperature. H<sub>2</sub>DCFDA (2&#x2019;,7&#x2019;-dichlorodihydrofluorescein diacetate) (Invitrogen, cat. no. D399, Waltham, MA) was added to 100 &#xb5;L cell samples at a concentration of 1 &#xb5;M in a 96-well black clear bottom plate and fluorescence was assessed at 480/520 nm excitation/emission using a SpectraMax iD5 Multi-Mode Microplate Reader (Molecular Devices, San Jose, CA). Experiments were performed in triplicate. Data were normalized to sample protein concentration, quantified via BCA assay, and reported as relative light units (RLU)/&#xb5;g protein. Statistical significance was determined via <italic>t</italic>-test analysis.</p>
</sec>
<sec id="s2_9">
<title>Determination of membrane potential</title>
<p>Membrane potential was assessed with JC-1 dye (Invitrogen, cat. no. T3168, Waltham, MA) in <italic>P. aeruginosa</italic> strains PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> harvested during both logarithmic and stationary phases of growth in LB, mAUM, and LM. JC-1 (10 &#xb5;M) was added to harvested bacteria (2.5 &#xb5;g of protein) in a 96-well black clear bottom plate and incubated for 10 minutes at room temperature in the dark, with or without oligomycin (1 &#xb5;M) and carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (5 &#xb5;M). The conditions in which membrane potential formation were analyzed include basal metabolic state (control), presence of oligomycin (1 &#xb5;M) (<xref ref-type="bibr" rid="B95">Symersky et&#xa0;al., 2012</xref>) to induce hyperpolarization by inhibiting ATP synthesis, and the presence of the protonophore CCCP (5 &#xb5;M) (<xref ref-type="bibr" rid="B21">Daniels et&#xa0;al., 1981</xref>) to depolarize the membrane. Fluorescence was measured at 480/520 and 535/596 nm excitation/emission for the green and red fluorescent states of the dye. Results were presented as the ratio of red to green fluorescence. Cell autofluorescence (red and green) was subtracted for all samples. After conducting the experiment in triplicate, the data were analyzed using <italic>t</italic>-test analysis.</p>
</sec>
<sec id="s2_10">
<title>Membrane preparation</title>
<p>Membranes were obtained from <italic>P. aeruginosa</italic> PA14 &#x394;<italic>bc</italic><sub>1</sub> grown in mAUM during the logarithmic stage of growth, as previously described (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>). Cell pellets were washed with KHE buffer (150 mM KCl, 20 mM HEPES, 1 mM EDTA, pH 7.5) and stored at -80 &#xb0;C until further use. Bacterial cells were thawed and resuspended in KHE buffer with 5 mM MgCl<sub>2</sub>, 10 &#xb5;g/mL DNase, and 1 mM PMSF. Cells were ruptured at 16,000 PSI using an Avestin Emulsiflex-C5 high pressure homogenizer (Ottawa, ON, Canada). Debris was separated from membranes via centrifugation at 10,000 &#xd7; <italic>g</italic> (4 &#xb0;C) and cell membranes were subsequently collected from supernatant via ultracentrifugation at 100,000 &#xd7; <italic>g</italic> (4 &#xb0;C). Membrane fractions were washed with KHE buffer and stored at -80 &#xb0;C.</p>
</sec>
<sec id="s2_11">
<title>Respiratory activity</title>
<p>The respiratory activity of <italic>P. aeruginosa</italic> PA14 &#x394;<italic>bc</italic><sub>1</sub> membranes harvested in the logarithmic phase following growth in mAUM was measured in a customized 1.6 mL glass oximetric chamber using a Clark-type oxygen electrode (YSI 5300) at 37 &#xb0;C using the methods previously detailed (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>) in triplicate. Assays were performed in KHE buffer with and without 1 &#xb5;M rotenone to inhibit complex I, with 200 &#xb5;M NADH or deamino-NADH to test for NADH oxidase activity, 10 mM lactate to test for lactate dehydrogenase activity, and 1 mM succinate to test for succinate dehydrogenase activity. Ubiquinol oxidase activity was determined using 50 &#xb5;M ubiquinone-1, 500 &#xb5;M 1,4-Dithiothreitol (DTT), and various concentrations of KCN to inhibit terminal oxidases.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Cytochrome <italic>bc</italic><sub>1</sub> is critical for growth in physiologically relevant medium</title>
<p>As reported in our previous work, cytochrome <italic>bc</italic><sub>1</sub> is critical for aerobic metabolism, ATP synthesis, and ion pumping in <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>). To assess the role of this enzyme in supporting proliferation under physiologically relevant conditions, growth of wild-type PA14 and the deletion mutant was assessed in media resembling the environment of common sites of infection, such as the urinary tract (mAUM) and the respiratory epithelium (LM), and compared to growth in nutrient-rich laboratory LB medium (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>). Previous work was carried out in a PA14 &#x394;<italic>bc</italic><sub>1</sub> transposon mutant (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>), which was not completely characterized at the genomic level, and may carry additional genetic modifications. In this work, we characterized the PA14 strain in which the <italic>bc<sub>1</sub></italic> gene was specifically eliminated using the lamba-red recombination system. Our group has previously validated mAUM for the analysis of adaptations in urine-like conditions (<xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>), while LM formulation has been used to study the growth of other pathogens in synthetic lung media (<xref ref-type="bibr" rid="B5">Ashworth et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B84">Ruhluel et&#xa0;al., 2022</xref>). Determining <italic>P. aeruginosa</italic> growth in urine-like medium and lung medium is critical for understanding how this pathogen adapts to the unique nutrient conditions of these environments that mimic infection sites, which can inform treatment strategies for chronic and acute urinary and respiratory infections such as (CA)UTIs and cystic fibrosis infections.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Growth of PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> in physiologically relevant medium. PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> growth (24&#xa0;h) in LB <bold>(A)</bold>, mAUM <bold>(B)</bold>, and LM <bold>(C)</bold>. Growth parameter analysis shows maximum growth <bold>(D)</bold>, growth rate <bold>(E)</bold>, and lag phase duration <bold>(F)</bold> of PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> grown in physiologically relevant medium. Results are presented as mean &#xb1; SD, <italic>n</italic>&#xa0;=&#xa0;3. Asterisks denote significant differences between PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> based on <italic>t</italic>-test analyses (*<italic>p</italic>&#xa0;&lt;&#xa0;0.05, **<italic>p</italic>&#xa0;&lt;&#xa0;0.01).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1763669-g001.tif">
<alt-text content-type="machine-generated">Six-panel figure showing bacterial growth data comparing wild type (WT) and &#x394;bc1 mutant. Panels A-C display line graphs of optical density at 620 nm over 25 hours in different media, with WT consistently outperforming &#x394;bc1. Panels D-F present bar graphs quantifying yield, growth rate, and lag phase in LB, mAUM, and LM media for both strains, with &#x394;bc1 exhibiting reduced yield and growth rate plus increased lag phase, significant differences marked by asterisks.</alt-text>
</graphic></fig>
<p>The growth of the wild-type and &#x394;<italic>bc</italic><sub>1</sub> mutant was followed in LB (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1A</bold></xref>), mAUM (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1B</bold></xref>), and LM (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1C</bold></xref>). In LB, the mutant strain exhibited significantly lower growth and reached a maximum OD<sub>620</sub> 32% lower than the wild-type (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1D</bold></xref>). Moreover, duplication time was reduced by 33% in the mutant (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1E</bold></xref>) and the lag phase duration was increased 1.5-fold (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1F</bold></xref>). These results confirm the important role of the <italic>bc</italic><sub>1</sub> complex in this growth condition, as shown from our previous work (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>). Similarly, in urine-like conditions (mAUM), maximal bacterial growth was decreased in the mutant, approximately 16% (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1B, D</bold></xref>). Moreover, the duplication rate was nearly half compared to wild-type strain (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1E</bold></xref>), while its lag phase was almost doubled (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1F</bold></xref>). The most pronounced difference in growth between the wild-type and the mutant is observed in LM (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1C</bold></xref>). The mutant had a 50% reduction in total growth (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1D</bold></xref>), more than doubling of the lag phase (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1F</bold></xref>), and a reduction in the growth rate &gt;50% (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1E</bold></xref>). The behavior exhibited by the mutant in these conditions suggests a hindered capacity to produce energy under physiologically relevant environments. This impairment may be due to the disruption of the electron transport chain in the mutant, highlighting the essential role of cytochrome <italic>bc</italic><sub>1</sub> in maintaining energy metabolism across diverse conditions. Collectively, these findings emphasize the importance of cytochrome <italic>bc</italic><sub>1</sub> as a key respiratory component that enables <italic>P. aeruginosa</italic> to adapt and proliferate in both urinary environments and nutrient-limited lung conditions.</p>
</sec>
<sec id="s3_2">
<title>Cytochrome <italic>bc</italic><sub>1</sub> is critical for virulence in <italic>P. aeruginosa</italic></title>
<p>To characterize the role of cytochrome <italic>bc</italic><sub>1</sub> in <italic>P. aeruginosa</italic> virulence and pathogenicity, 5637 human epithelial bladder cells were infected with either wild-type or &#x394;<italic>bc</italic><sub>1</sub> mutant strains, and bladder cell viability was assessed (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2B</bold></xref>). At 2 hpi, neither strain impacted bladder cell survival, indicating that this timeframe is necessary for the bacterial cells to express virulence factors. At 4 hpi, the viability of cells infected with wild-type <italic>P. aeruginosa</italic> drops sharply to 23% (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2A, B</bold></xref>). On the other hand, 62% of cells infected with the mutant strain are still viable (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2A, B</bold></xref>). By the 6-hour time point, the wild-type strain eliminated all viable human cells, while in the mutant 12% of the infected cells are still viable. Even though cellular viability decreases over time in both conditions, virulence is clearly diminished by the lack of cytochrome <italic>bc</italic><sub>1</sub>, which may be due to alterations in bacterial virulence factor production. Thus, we sought to investigate how the mutation attenuates pathogenicity during host cell infection. Following 6-hour bladder cell infection with PA14 or PA14 &#x394;<italic>bc</italic><sub>1</sub> at MOI 10, culture media was collected, filtered (0.2 &#xb5;m), and applied to uninfected bladder epithelial cells for 6 hours. Subsequent evaluation of cellular viability shows that neither wild-type nor &#x394;<italic>bc</italic><sub>1</sub> mutant (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2C, D</bold></xref>) produce soluble factors that induce bladder cell death in the conditions tested, as the bladder cells exposed to the filtered media retained 100% cell viability (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2D</bold></xref>). This suggests that the virulence factor(s) downregulated in the mutant requires cell-to-cell contact-mediated mechanisms.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Human bladder epithelial cell viability following infection with PA14 or PA14 &#x394;<italic>bc</italic><sub>1.</sub><bold>(A)</bold> Representative images of 5637 cells infected with PA14 or PA14 &#x394;<italic>bc</italic><sub>1</sub> at a multiplicity of infection of 10 for 4 hours and stained with 1:1 PBS:trypan blue, followed by microscopy imaging. Scale bar = 100 &#xb5;m. 5637 viability was quantified as percentage of live cells (unstained) versus all cells [unstained plus blue-stained (dead)] of 10 different random fields at 2, 4, and 6 hpi <bold>(B)</bold>. Results are presented as mean &#xb1; SD, <italic>n</italic>&#xa0;=&#xa0;3. Cell culture supernatant following 6 hours of infection with PA14 or PA14 &#x394;<italic>bc</italic><sub>1</sub> was filtered and reapplied to 5637 bladder epithelial cells and incubated for 6 hours. <bold>(C)</bold> Representative images of 5637 cells infected with filtered supernatant of PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> stained with 1:1 PBS:trypan blue, and imaged via microscopy. Viability of cells infected with filtered supernatant was quantified as percentage of live cells (non-stained) versus all cells [non-stained plus blue-stained (dead)] of 10 different random fields and reported as mean &#xb1; SD, <italic>n</italic>&#xa0;=&#xa0;3 <bold>(D)</bold>. Statistical differences between PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> were evaluated via <italic>t</italic>-test analysis (*<italic>p</italic>&#xa0;&lt;&#xa0;0.05).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1763669-g002.tif">
<alt-text content-type="machine-generated">Panel A shows two microscope images at four hours post-infection with dense blue-stained cells for PA14 and fewer blue-stained cells for PA14 &#x394;bc1. Panel B displays a bar graph measuring 5637 cell viability in percent across two, four, and six hours post-infection, comparing wild-type and &#x394;bc1 strains, with viability decreasing more rapidly in wild-type. Panel C presents microscope images at six hours post-infection with unstained cells for both strains. Panel D displays a bar graph showing similar high viability in both strains at six hours post-infection.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_3">
<title>Cytochrome <italic>bc</italic><sub>1</sub> is essential for T3SS functionality</title>
<p><italic>P. aeruginosa</italic> possesses a type III secretion system (T3SS) that is critical for contact-based cytotoxicity, enabling the injection of proteins into the host cell cytoplasm (<xref ref-type="bibr" rid="B35">Hauser, 2009</xref>; <xref ref-type="bibr" rid="B94">Stover et&#xa0;al., 2000</xref>). PA14 secretes exoT, exoU, and exoY effector proteins, which function distinctly yet complementarily throughout the infection process (<xref ref-type="bibr" rid="B26">Filloux, 2011</xref>). ExoU is the major virulence factor <italic>in vivo</italic> and <italic>in vitro</italic> due to its phospholipase activity, which compromises the host membrane, while exoT and exoY have been shown to play a minimal role during infection (<xref ref-type="bibr" rid="B35">Hauser, 2009</xref>; <xref ref-type="bibr" rid="B48">Kazmierczak and Engel, 2002</xref>; <xref ref-type="bibr" rid="B51">Krall et&#xa0;al., 2000</xref>; <xref ref-type="bibr" rid="B56">Lee et&#xa0;al., 2005</xref>; <xref ref-type="bibr" rid="B78">Phillips et&#xa0;al., 2003</xref>; <xref ref-type="bibr" rid="B85">Sato et&#xa0;al., 2003</xref>). Relative fold-change analysis of T3SS effector gene expression (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3A</bold></xref>) showed a 53% decrease in <italic>exoT</italic> and a 60% decrease in <italic>exoU</italic> expression in the deletion mutant strain. However, <italic>exoY</italic> expression remained unchanged between the strains. Interestingly, it was previously reported that <italic>P. aeruginosa</italic> strains lacking the gene encoding for <italic>exoY</italic> or failing to express the protein were more toxic to lung epithelial cells than strains expressing the toxin (<xref ref-type="bibr" rid="B89">Silistre et&#xa0;al., 2021</xref>), indicating that <italic>exoY</italic> presence is not detrimental to host cells. These results demonstrate that deletion of cytochrome <italic>bc</italic><sub>1</sub> severely hinders <italic>P. aeruginosa</italic> virulence (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2B</bold></xref>, <xref ref-type="fig" rid="f3"><bold>3A</bold></xref>) by downregulating expression of the most cytotoxic effectors <italic>exoT</italic> and <italic>exoU</italic>, plausibly due to its compromised respiratory chain function and thus bioenergetic processes. The <italic>P. aeruginosa</italic> T3SS needle complex relies on PscN, an ATPase that drives the translocation of effector proteins into host cells (<xref ref-type="bibr" rid="B35">Hauser, 2009</xref>). Deletion of cytochrome <italic>bc</italic><sub>1</sub> in PA14 disrupts oxidative phosphorylation and diminishes cellular ATP generation (see below), thereby limiting the energy supply required for T3SS function. As a result, the molecular syringe may operate less efficiently, leading to reduced effector protein secretion and attenuated host cell damage.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Effects of cytochrome <italic>bc</italic><sub>1</sub> deletion on <italic>P. aeruginosa</italic> virulence. 5637 cells were infected with PA14 or PA14 &#x394;<italic>bc</italic><sub>1</sub> for 4 hours at a multiplicity of infection of 10. <bold>(A)</bold> Relative mRNA expression of the T3SS effectors <italic>exoT</italic>, <italic>exoU</italic>, and <italic>exoY</italic> was subsequently quantified via qPCR. Results are presented as mean &#xb1; SE, <italic>n</italic>&#xa0;=&#xa0;9. <bold>(B)</bold> Kaplan-Meier survival curves of eight-week-old female BALB/cJ mice following systemic infection with PA14 (<italic>n</italic>&#xa0;=&#xa0;17) or PA14 &#x394;<italic>bc</italic><sub>1</sub> (<italic>n</italic>&#xa0;=&#xa0;14) administered through lateral tail vein. PBS was used as a vehicle control (<italic>n</italic>&#xa0;=&#xa0;7). <bold>(C)</bold> Biofilm production by PA14 or PA14 &#x394;<italic>bc</italic><sub>1</sub> in LB, mAUM, and LM following 48 hour incubation (n = 3). Statistical significance between PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> was determined by <italic>t</italic>-test (*<italic>p</italic>&#xa0;&lt;&#xa0;0.05, **<italic>p</italic>&#xa0;&lt;&#xa0;0.01, ***<italic>p</italic>&#xa0;&lt;&#xa0;0.001). Mouse survival significance was evaluated using the log-rank test (***<italic>p</italic>&#xa0;&lt;&#xa0;0.001).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1763669-g003.tif">
<alt-text content-type="machine-generated">Panel A shows a bar graph comparing relative fold change of ExoT, ExoU, and ExoY between wild type (WT) and &#x394;bc1 mutant, with significant reductions for ExoT and ExoU in &#x394;bc1. Panel B presents a Kaplan-Meier survival plot, indicating reduced survival over time in WT compared to &#x394;bc1 and PBS groups, with PBS showing the highest survival. Panel C displays a bar chart of biofilm formation (Abs595) in LB, mAUM, and LM media, where WT forms significantly more biofilm than &#x394;bc1, particularly in LM medium. Statistical significance is indicated with asterisks.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_4">
<title>Deletion of the <italic>bc</italic><sub>1</sub> complex decreases virulence <italic>in vivo</italic></title>
<p>To further evaluate the impact of cytochrome <italic>bc</italic><sub>1</sub> deletion on <italic>P. aeruginosa</italic> pathogenicity, the effects of the mutant were assessed on a systemic infection model in mice, evaluating survival following infection with wild-type or &#x394;<italic>bc</italic><sub>1</sub> cells. As shown in <xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3B</bold></xref>, &lt;20% of mice infected with wild-type PA14 survived beyond seven days post-infection. Remarkably, deletion of cytochrome <italic>bc</italic><sub>1</sub> increased survival to 93%, indicating that this enzyme is essential for virulence <italic>in vivo</italic>. The deletion mutant is completely avirulent, as the survivability did not differ statistically from that of the PBS control group (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3B</bold></xref>). This effect may be attributed to the bacterium&#x2019;s energy deficit paired with lack of virulence factor production, resulting in an inability to resist host immune response. Indeed, <italic>exoU</italic> has been associated with phagocyte killing (<xref ref-type="bibr" rid="B24">Diaz et&#xa0;al., 2008</xref>), thereby compromising host defense mechanisms. Consequently, diminished <italic>exoU</italic> expression in the &#x394;<italic>bc</italic><sub>1</sub> mutant strain may mitigate virulence and would promote bacterial clearance in mice.</p>
</sec>
<sec id="s3_5">
<title>Role of the <italic>bc</italic><sub>1</sub> complex in biofilm formation</title>
<p>Biofilm is a critical virulence factor of <italic>P. aeruginosa</italic>, contributing to both infection establishment and multidrug resistance in different tissues, including the lung and urinary tract (<xref ref-type="bibr" rid="B64">Maurice et&#xa0;al., 2018</xref>). In this work, we further characterized the role of the <italic>bc</italic><sub>1</sub> complex in pathogenicity by evaluating biofilm formation in physiologically relevant media. As shown in <xref ref-type="fig" rid="f3"><bold>Figures&#xa0;3C</bold></xref>, in LB medium, both wild-type and mutant strains produce comparable amounts of biofilm. In contrast, a significant difference between the wild-type and mutant is observed in LM, where the mutant had a seven-fold decrease in biofilm formation. Interestingly, in mAUM, the cells could not produce significant amounts of biofilm. These findings underscore the critical role of the <italic>bc</italic><sub>1</sub> complex in facilitating biofilm formation in LM, suggesting that the enzyme may serve as a promising therapeutic target for disrupting <italic>P. aeruginosa</italic> in biofilm-associated infections, which may be particularly relevant in lung infections, in conditions such as cystic fibrosis.</p>
</sec>
<sec id="s3_6">
<title>Role of the <italic>bc</italic><sub>1</sub> complex in ATP generation, reactive oxygen species production, and membrane potential in physiologically relevant media</title>
<p>As shown in our previous studies, the electron transport chain is essential for ATP generation in <italic>P. aeruginosa</italic>, contributing to the formation of the proton gradient, which drives energy production (<xref ref-type="bibr" rid="B67">Mitchell, 2011</xref>). ATP levels of PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> were measured in cells cultured in LB, mAUM, and LM to determine the relevance of cytochrome <italic>bc</italic><sub>1</sub> in ATP generation under physiologically relevant conditions (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4A</bold></xref>). In laboratory LB media, no difference was found in ATP content between the wild-type strain and mutant in stationary or logarithmic phases, which is consistent with the minor changes in growth found in this condition. However, in mAUM, the ATP content of the &#x394;<italic>bc</italic><sub>1</sub> mutant was 44% less than the wild-type strain during stationary growth. This effect was more pronounced during the logarithmic phase of growth in mAUM, as the mutant produced 92% less ATP than the wild-type strain. In lung media, ATP content was severely decreased in the &#x394;<italic>bc</italic><sub>1</sub> mutant in both stationary and logarithmic phases, by 86% and 79% compared to the wild-type strain, respectively. These results clearly demonstrate that the <italic>bc</italic><sub>1</sub> complex, while not absolutely essential for growth, is critical in <italic>P. aeruginosa</italic> bioenergetics and physiology. Remarkably, the effects of the mutant on ATP content closely correlate with the effects seen in the growth parameters under physiologic culture conditions as shown in <xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>. Altogether, the data indicate that cytochrome <italic>bc</italic><sub>1</sub> is highly relevant to energy generation in physiologic media, which explains the almost complete lack of virulence of the mutant in animal models.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Assessment of PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> bioenergetics in physiologically relevant medium during stationary and logarithmic phases. ATP levels <bold>(A)</bold>, ROS production <bold>(B)</bold>, and membrane potential in LB <bold>(C)</bold>, mAUM <bold>(D)</bold>, and LM <bold>(E)</bold> were evaluated in PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> in stationary (Sta) and logarithmic (Log) phases. Results are reported as mean &#xb1; SD, <italic>n</italic>&#xa0;=&#xa0;3. Statistical differences between PA14 and PA14 &#x394;<italic>bc</italic><sub>1</sub> were analyzed via <italic>t</italic>-test (*<italic>p</italic>&#xa0;&lt;&#xa0;0.05, **<italic>p</italic>&#xa0;&lt;&#xa0;0.01, ***<italic>p</italic>&#xa0;&lt;&#xa0;0.001).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1763669-g004.tif">
<alt-text content-type="machine-generated">Five-panel figure comparing wild-type (black bars) and &#x394;bc1 mutant (white bars) strains for ATP levels (panel A), ROS production (panel B), and JC-1 aggregate/monomer ratios (panels C&#x2013;E) across various growth conditions, with statistical significance indicated by asterisks.</alt-text>
</graphic></fig>
<p>As reported in the literature, cytochrome <italic>bc</italic><sub>1</sub> is one of the main contributors to reactive oxygen species production (<xref ref-type="bibr" rid="B14">Brand, 2016</xref>; <xref ref-type="bibr" rid="B87">Seaver and Imlay, 2004</xref>). To fully characterize the metabolic role of the <italic>bc</italic><sub>1</sub> complex in <italic>P. aeruginosa</italic>, ROS production was evaluated in the mutant and wild-type strain. Our results show that ROS production was significantly modified in the mutant strain in all three media tested (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4B</bold></xref>). In LB medium during stationary and logarithmic stages of growth, ROS production by PA14 &#x394;<italic>bc</italic><sub>1</sub> significantly decreased compared to the wild-type strain, by 78% and 60%, respectively. In LM, there was no difference between the two strains during logarithmic growth, while a nearly 10-fold decrease in ROS production was observed in the mutant strain during the stationary phase. The decrease in ROS production by the mutant in these conditions is expected, as the <italic>bc</italic><sub>1</sub> complex is a main contributing factor to oxygen radicals (<xref ref-type="bibr" rid="B76">Pagacz et&#xa0;al., 2021</xref>). Surprisingly, in mAUM, ROS production by the mutant strain increased significantly compared with PA14, showing a 3.8- and 2.2-fold increase in stationary and logarithmic growth phases, respectively. This increase likely reflects the pathogen&#x2019;s reliance on cytochrome <italic>bc</italic><sub>1</sub> in mAUM, where it drives ion pumping and respiration (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>). The lack of the <italic>Pseudomonas</italic> quinolone signal (PQS) in the mutant (<xref ref-type="bibr" rid="B92">Soh et&#xa0;al., 2021</xref>), which is linked to the generation of anti-oxidative responses (<xref ref-type="bibr" rid="B36">H&#xe4;ussler and Becker, 2008</xref>), may also contribute to this surge in ROS in mAUM.</p>
<p>As discussed above, our previous work shows that cytochrome <italic>bc</italic><sub>1</sub> is a critical contributor to ion pumping in the <italic>P. aeruginosa</italic> respiratory chain (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>), which links the operation of the respiratory chain to ATP production. To evaluate the role of cytochrome <italic>bc</italic><sub>1</sub> on membrane potential, the fluorescent signal of the voltage-dependent JC-1 dye was studied in the wild-type and &#x394;<italic>bc</italic><sub>1</sub> mutant in LB, mAUM, and LM (<xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4C-E</bold></xref>). The addition of oligomycin produced relatively small changes in membrane potential and thus the data were omitted from this work for clarity. In LB, wild-type cells produced a significant membrane potential in the stationary phase, which decreased in the logarithmic phase. In this condition, no significant differences were found in the &#x394;<italic>bc</italic><sub>1</sub> mutant (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4C</bold></xref>), which correlates with the small differences observed in growth and ATP content. This effect could be due to the significant role that other respiratory enzymes, such as NQR, <italic>bd</italic> oxidase, and <italic>bo</italic><sub>3</sub> oxidase, play in membrane potential generation, which could compensate for lack of the <italic>bc</italic><sub>1</sub> complex, as discussed in a previous work (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>). In mAUM (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4D</bold></xref>), the membrane potential produced by wild-type cells during stationary phase nearly doubled compared to that of LB, and did not decrease in the logarithmic state, which could be due to the activation of the respiratory chain observed in these conditions (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>). Remarkably, in mAUM, the &#x394;<italic>bc</italic><sub>1</sub> mutant did not exhibit a difference in membrane potential compared to the wild-type strain. Finally, membrane potential measurements for cells cultured in LM were carried out in fresh LM instead of PBS, which was used for other conditions, as LM-grown cells displayed an undetectable membrane potential when measured in PBS. The data shown in <xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4E</bold></xref> indicate that in this condition, the cells produce a small but detectable membrane potential, which was significantly increased in the mutant during logarithmic growth. Experiments were also carried out with DiOC<sub>2</sub>(3), another widely used membrane potential indicator (<xref ref-type="bibr" rid="B73">Novo et&#xa0;al., 1999</xref>; <xref ref-type="bibr" rid="B77">Pan et&#xa0;al., 2017</xref>), obtaining similar results (not shown). It is likely that the nutrient composition of LM does not allow for a very active metabolism, reflected in the lowest growth rate of all conditions (approximately 20% compared to LB medium). In spite of the significant changes in the metabolic parameters that we have measured, including ATP content, in the case of membrane potential, the mutant only showed a significant increase compared to the wild-type strain during logarithmic growth in LM, which indicates that the respiratory chain in the mutant is adapted to the lack of the <italic>bc</italic><sub>1</sub> complex in most conditions, likely by decreasing the expression of pathways that require active H<sup>+</sup>- transport, which would result in diminished growth and an avirulent phenotype.</p>
</sec>
<sec id="s3_7">
<title>Metabolic adaptations of the cytochrome <italic>bc</italic><sub>1</sub> mutant</title>
<p>As shown in this manuscript and our previous work, the <italic>bc</italic><sub>1</sub> complex has a critical role in cell physiology. Nonetheless, this enzyme is not essential for <italic>P. aeruginosa</italic>, as the cells are able to adapt to its elimination and can grow in all physiologic media tested, although at lower rates. However, the significant metabolic challenge imposed by this deletion has a deleterious effect on virulence. To understand the adaptability of <italic>P. aeruginosa</italic>, the respiratory chain of the mutant was fully characterized as previously described (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>). <italic>P. aeruginosa</italic> has three NADH:ubiquinone oxidoreductases: Complex I, NQR, and NDH-2, which are not homologous and can be distinguished by their substrate and inhibitor sensitivity (<xref ref-type="bibr" rid="B23">Degli Esposti, 1998</xref>; <xref ref-type="bibr" rid="B63">Matsushita et&#xa0;al., 1987</xref>; <xref ref-type="bibr" rid="B101">Yagi, 1991</xref>; <xref ref-type="bibr" rid="B102">Zambrano and Kolter, 1993</xref>; <xref ref-type="bibr" rid="B103">Zhou et&#xa0;al., 1999</xref>; <xref ref-type="bibr" rid="B104">Zickermann et&#xa0;al., 2000</xref>). NQR and complex I, which are proton pumps (<xref ref-type="bibr" rid="B81">Raba et&#xa0;al., 2018</xref>), are capable of utilizing both NADH and deamino-NADH (<xref ref-type="bibr" rid="B63">Matsushita et&#xa0;al., 1987</xref>; <xref ref-type="bibr" rid="B103">Zhou et&#xa0;al., 1999</xref>). Complex I is able to do so without showing substrate preference, and is inhibited by rotenone (<xref ref-type="bibr" rid="B23">Degli Esposti, 1998</xref>; <xref ref-type="bibr" rid="B104">Zickermann et&#xa0;al., 2000</xref>), while NQR is rotenone insensitive (<xref ref-type="bibr" rid="B103">Zhou et&#xa0;al., 1999</xref>). In contrast, NDH-2, which does not have proton pumping activity, specifically uses NADH as a substrate and is resistant to rotenone (<xref ref-type="bibr" rid="B63">Matsushita et&#xa0;al., 1987</xref>; <xref ref-type="bibr" rid="B101">Yagi, 1991</xref>; <xref ref-type="bibr" rid="B102">Zambrano and Kolter, 1993</xref>). Thus, the activities of these enzymes can be differentiated by measuring the respiratory activity with NADH, deamino-NADH, and rotenone, as showed previously by our group (<xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>). <xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5A</bold></xref> depicts the oxygen consumption rate (OCR) of <italic>P. aeruginosa</italic> &#x394;<italic>bc</italic><sub>1</sub> membranes harvested in mAUM during the logarithmic growth stage using NADH, deamino-NADH, succinate, and lactate as substrates. These substrates are employed by the main dehydrogenases involved in the pathogen&#x2019;s respiratory chain in mAUM, contributing to the ubiquinone/ubiquinol pool that can ultimately be utilized by the terminal oxidases (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>). In comparison to the succinate and lactate dehydrogenase activities, the NADH oxidase activity in the mutant exhibits the highest OCR, indicating its critical role in respiration. NADH activity was mostly insensitive to rotenone, indicating that complex I is minimally involved, facilitating approximately 20% of electron transfer. Moreover, deamino-NADH oxidation was relatively lower compared to the wild-type cells (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>), revealing that NQR and complex I contribute &lt;35% of the NADH dehydrogenase activity in the cytochrome <italic>bc</italic><sub>1</sub> mutant, and that the mutant mainly relies on NDH-2, supporting around 65% of electron transfer from NADH. This result contrasts sharply with wild-type <italic>P. aeruginosa</italic>, in which 75% of the NADH dehydrogenase activity is provided by NQR (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Metabolic adaptations of PA14 &#x394;<italic>bc</italic><sub>1</sub>. Oxygen consumption rates of PA14 &#x394;<italic>bc</italic><sub>1</sub> membranes harvested during the logarithmic phase of growth in mAUM were quantified in the presence of different substrates (200 &#xb5;M NADH, 200 &#xb5;M deamino-NADH, 1 &#xb5;M rotenone, 1 mM succinate, 10 mM lactate) <bold>(A)</bold>. Ubiquinol oxidase contribution was assessed via quantification of oxygen consumption rates at various concentrations of KCN with 50 &#xb5;M ubiquinone-1 and 500 &#xb5;M 1,4-Dithiothreitol (DTT) <bold>(B)</bold>. All results are reported as mean &#xb1; SD, <italic>n</italic>&#xa0;=&#xa0;3.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1763669-g005.tif">
<alt-text content-type="machine-generated">Panel A shows a bar graph comparing oxygen consumption rate (OCR) in nmol per minute per milligram protein in the presence of various substrates: NADH, DA-NADH, rotenone plus NADH, succinate, and lactate. Panel B presents a scatter plot with fitted curve showing the percentage of OCR decreasing as potassium cyanide (KCN) concentration increases from zero to five thousand micromolar. Both plots include error bars for each data point.&lt;/alt-text&gt;&lt;/fig&gt;</alt-text>
</graphic></fig>
<p>To assess the respiratory contribution of terminal oxidases in the cytochrome <italic>bc</italic><sub>1</sub> mutant, respiratory ubiquinol oxidase relative activities were analyzed through KCN titration, as previously described (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5B</bold></xref>) (<xref ref-type="bibr" rid="B30">Gonz&#xe1;lez-Montalvo et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>). In addition to the <italic>bc</italic><sub>1</sub> complex, which feeds cytochrome <italic>c</italic> oxidases, the respiratory chain of <italic>P. aeruginosa</italic> contains two ubiquinol oxidases: cytochrome <italic>bo</italic><sub>3</sub> oxidase (<xref ref-type="bibr" rid="B3">Arai, 2011</xref>), which is sensitive to cyanide in the 10-30 &#x3bc;M range (<xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>), and the cyanide-insensitive <italic>bd</italic> oxidase, which can be inhibited in the mM range (<xref ref-type="bibr" rid="B4">Arai et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>). In logarithmic phase cells cultured in mAUM, the primary oxidase employed by the &#x394;<italic>bc</italic><sub>1</sub> mutant is the cyanide-insensitive <italic>bd</italic> oxidase, carrying out nearly 70% of the activity, while the remaining 30% can be attributed to <italic>bo</italic><sub>3</sub> oxidase. According to our data, the respiratory chain in the wild-type is composed of NQR and <italic>bc</italic><sub>1</sub> in addition to cytochrome oxidases, and in the mutant it switches to NDH-2 and <italic>bd</italic> oxidase, which significantly reduces the ability of the respiratory chain to pump protons and produce ATP (see below).</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Infections caused by <italic>P. aeruginosa</italic> in the urinary tract and lungs pose a major healthcare challenge, largely due to the pathogen&#x2019;s MDR profile (<xref ref-type="bibr" rid="B82">Reynolds and Kollef, 2021</xref>). Despite its clinical importance and impact, the metabolic strategies that enable <italic>P. aeruginosa</italic> to colonize distinct physiologic environments and contribute to virulence remain poorly understood. Prior research has revealed elevated activity of the Krebs and glyoxylate cycles in <italic>P. aeruginosa</italic> in both chronic lung infections (<xref ref-type="bibr" rid="B40">Hoboth et&#xa0;al., 2009</xref>) and urinary tract infections (<xref ref-type="bibr" rid="B12">Berger et&#xa0;al., 2014</xref>), highlighting the importance of aerobic metabolism during infection. Our group previously examined the aerobic metabolism of <italic>P. aeruginosa</italic> in media resembling urine, mAUM (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>), identifying cytochrome <italic>bc</italic><sub>1</sub> as the major contributor to respiration and ion pumping, which indicated its potential as an antibiotic target (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>). Cytochrome <italic>bc</italic><sub>1</sub> inactivation by transposon mutagenesis previously showed a reduction in virulence factor production and pathogenicity of <italic>P. aeruginosa</italic> PAO1 (<xref ref-type="bibr" rid="B88">Shen et&#xa0;al., 2021</xref>). However, a thorough investigation of the mechanism by which the <italic>bc</italic><sub>1</sub> complex regulates homeostasis and virulence has not been carried out, particularly in the PA14 strain, which is relevant for clinical cases due to its high pathogenicity. In this manuscript, we have expanded our studies to fully understand the role of this enzyme in <italic>P. aeruginosa</italic> physiology in critical infection sites: the lungs and the urinary tract.</p>
<sec id="s4_1">
<title>Cytochrome <italic>bc</italic><sub>1</sub> is critical for <italic>P. aeruginosa</italic> growth in urinary- and lung-like environments</title>
<p>In our previous work, we reported that the growth of a PA14 cytochrome <italic>bc</italic><sub>1</sub> transposon mutant (<xref ref-type="bibr" rid="B59">Liberati et&#xa0;al., 2006</xref>) showed significant defects in maximum growth and growth rate, and an increase in the lag phase (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>). In this study, we obtained a deletion mutant of cytochrome <italic>bc</italic><sub>1</sub> in PA14 using the lambda-red recombinase method (<xref ref-type="bibr" rid="B22">Datsenko and Wanner, 2000</xref>), which specifically eliminates the gene of interest and minimizes unintended effects of transposon mutagenesis, which can inactivate neighboring genes or regulatory sequences (<xref ref-type="bibr" rid="B22">Datsenko and Wanner, 2000</xref>). Moreover, we expanded our studies to LM (<xref ref-type="bibr" rid="B84">Ruhluel et&#xa0;al., 2022</xref>) to understand the effects of the mutant in the highly relevant lung environment, particularly for opportunistic infections in cystic fibrosis. Our results show significant growth defects in the mutant, including an increase in the lag phase (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1F</bold></xref>) and decreases in the growth rate (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1E</bold></xref>) and yield (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1D</bold></xref>) in rich laboratory LB media (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1A</bold></xref>), which were considerably more pronounced in physiologic media. The differences observed among culture media may be due to their specific composition. For instance, mAUM contains lactate and citrate as main carbon sources (<xref ref-type="bibr" rid="B30">Gonz&#xe1;lez-Montalvo et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>), while LM is composed mostly of amino acids (<xref ref-type="bibr" rid="B84">Ruhluel et&#xa0;al., 2022</xref>). In both mAUM and LM, an active Krebs cycle and respiratory chain are required for growth, underscoring the relevance of the <italic>bc</italic><sub>1</sub> complex in these conditions due to its involvement in electron transport. In mAUM, <italic>P. aeruginosa</italic> relies on a tightly coupled, oxidative TCA cycle with strong gluconeogenic flux and high energetic efficiency, which could be related to faster growth. In contrast, in LM the metabolism becomes flexible and nitrogen-driven, with amino acid catabolism feeding multiple TCA entry points. In our previous work, the relative contribution of respiratory enzymes to ATP production was calculated, demonstrating that the <italic>bc</italic><sub>1</sub> complex is the main respiratory enzyme in mAUM, contributing more than 50% of the respiratory chain H<sup>+</sup>-pumping activity (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>). The relevance of the <italic>bc</italic><sub>1</sub> complex in <italic>P. aeruginosa</italic> is confirmed in this work by the slow growth of the mutant in mAUM (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1B, E</bold></xref>). Remarkably, our data show that the <italic>bc</italic><sub>1</sub> complex is also critical for proliferation in the lung-mimicking environment, where a sharp reduction in growth was observed in the mutant in comparison to the wild-type strain (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1C, E</bold></xref>). Relative to mAUM, the wild-type strain grew to higher OD<sub>620</sub> in LM but exhibited a lower growth rate. In the mutant, we observed an extended lag phase, indicating that cytochrome <italic>bc</italic><sub>1</sub> plays important roles in adaptability to nutritional sources, particularly to the amino acid-rich lung media, which mirrors the conditions typically observed in cystic fibrosis lungs (<xref ref-type="bibr" rid="B10">Barth and Pitt, 1996</xref>). Amino acid catabolism feeds directly into the Krebs cycle, generating reducing equivalents that drive the electron transport chain. Thus, in an amino acid-rich medium such as LM, the cytochrome <italic>bc</italic><sub>1</sub> mutation is expected to produce a significant growth defect.</p>
<p>Biofilms are hallmark contributors to the persistence of chronic urinary and pulmonary infections and are an important virulence factor of <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="B27">Folkesson et&#xa0;al., 2012</xref>; <xref ref-type="bibr" rid="B62">Mancuso et&#xa0;al., 2023</xref>). Our results show that in LB, the wild-type strain was able to produce a significant amount of biofilm, which was not affected by the lack of the <italic>bc</italic><sub>1</sub> complex. On the other hand, in mAUM, PA14 produced moderate amounts of biofilm, approximately 28% compared to the LB condition. Interestingly, in mAUM, the &#x394;<italic>bc</italic><sub>1</sub> mutant showed a decrease of 50% in biofilm production compared to the wild-type (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3C</bold></xref>). Indeed, a previous report indicates that in urea-rich environments, such as those in the urinary tract and mAUM, quorum sensing is repressed in <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="B19">Cole et&#xa0;al., 2018</xref>), which plays an essential role in biofilm development (<xref ref-type="bibr" rid="B66">Miranda et&#xa0;al., 2022</xref>). In LM, the wild-type strain showed nearly a 3-fold increase in biofilm production compared to LB that could be due to high mucin content in LM, which may aid in bacterial attachment and aggregation, mimicking cystic fibrosis environments (<xref ref-type="bibr" rid="B53">Landry et&#xa0;al., 2006</xref>). Remarkably, biofilm production was severely diminished in the mutant strain (seven-fold reduction). The attenuation in biofilm production by the &#x394;<italic>bc</italic><sub>1</sub> mutant in physiologic media can be attributed to a decrease in electron flow through cytochrome <italic>bc</italic><sub>1</sub>, which diminishes both aerobic respiration via terminal cytochrome <italic>c</italic> oxidases and anaerobic respiration via denitrification. Several reports indicate that in the lung environment, especially during cystic fibrosis and in biofilms, <italic>P. aeruginosa</italic> switches its metabolism and is able to generate energy anaerobically via denitrification (<xref ref-type="bibr" rid="B34">Hassett et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B75">Ojoo et&#xa0;al., 2005</xref>; <xref ref-type="bibr" rid="B100">Williams et&#xa0;al., 2007</xref>), which employs nitrate and nitrite reductases dependent on cytochrome <italic>bc</italic><sub>1</sub> activity (<xref ref-type="bibr" rid="B3">Arai, 2011</xref>; <xref ref-type="bibr" rid="B100">Williams et&#xa0;al., 2007</xref>). A previous report also demonstrates that inactivation of the cytochrome <italic>c</italic><sub>1</sub> subunit of cytochrome <italic>bc</italic><sub>1</sub> halted <italic>P. aeruginosa</italic> growth in anaerobic conditions using nitrite as an electron acceptor (<xref ref-type="bibr" rid="B33">Hasegawa et&#xa0;al., 2003</xref>). Alternatively, although the arginine deiminase (ADI) pathway is also utilized by <italic>P. aeruginosa</italic> under conditions when oxygen and nitrate are not present (<xref ref-type="bibr" rid="B100">Williams et&#xa0;al., 2007</xref>), increased expression of key ADI enzymes has been observed in CF lungs, indicating that this pathway is also employed during such infections (<xref ref-type="bibr" rid="B41">Hogardt and Heesemann, 2013</xref>). However, our data demonstrate that denitrification via the cytochrome <italic>bc</italic><sub>1</sub>-dependent respiratory chain is the predominant pathway supporting energy generation in <italic>P. aeruginosa</italic> biofilms under the tested conditions, as exemplified by the decreased biofilm produced by the mutant. As biofilm formation is a key virulence factor in <italic>P. aeruginosa</italic> in both pulmonary and urinary tract infections, reducing biofilm is critical for decreasing persistence, reducing colonization, and enhancing antibiotic efficacy (<xref ref-type="bibr" rid="B70">Narten et&#xa0;al., 2012</xref>; <xref ref-type="bibr" rid="B18">Ciofu et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B91">Soares et&#xa0;al., 2020</xref>). By identifying the metabolic relevance of cytochrome <italic>bc</italic><sub>1</sub> for <italic>P. aeruginosa</italic> biofilm, we have demonstrated that therapeutic targeting of cytochrome <italic>bc</italic><sub>1</sub> holds promise, particularly in the pulmonary environment of cystic fibrosis patients, which may also enhance current antibiotic efficacy via synergistic interactions. Our data and previous findings highlight the potential of cytochrome <italic>bc</italic><sub>1</sub> as an antibiotic target that can be exploited in both aerobic and anaerobic conditions.</p>
</sec>
<sec id="s4_2">
<title>Role of cytochrome <italic>bc</italic><sub>1</sub> in virulence regulation</title>
<p>Our data show that deletion of cytochrome <italic>bc</italic><sub>1</sub> reduces <italic>P. aeruginosa</italic> growth in physiologic conditions and decreases the virulence of cells in an <italic>in vitro</italic> infection model of 5637 human urinary bladder carcinoma cells, a system that recapitulates part of the urinary tract infection. In these conditions, the mutant has a significant attenuation of virulence, as there is a 39% difference between the death of &#x394;<italic>bc</italic><sub>1</sub>-infected and PA14-infected cells (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2A, B</bold></xref>), which is not mediated by the secretion of virulence factors, but is contact-based (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2C, D</bold></xref>). qPCR experiments show that the mutant decreases expression of the essential T3SS components <italic>exoT</italic> and <italic>exoU</italic>, while <italic>exoY</italic> remains unchanged (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3A</bold></xref>). <italic>ExoU</italic> is encoded on the PAPI-2 pathogenicity island in PA14, which contains other non-<italic>exoU</italic> virulence genes (<xref ref-type="bibr" rid="B32">Harrison et&#xa0;al., 2010</xref>). The decrease of <italic>exoU</italic> expression in the mutant strain suggests that other virulence genes encoded within PAPI-2 may also have downregulated expression. Moreover, previous findings revealed that the respiratory chain is critical for <italic>P. aeruginosa</italic> pathogenicity in a <italic>Galleria mellonella</italic> model (<xref ref-type="bibr" rid="B96">Torres et&#xa0;al., 2019</xref>). Prior reports also show that the elimination of the <italic>bc</italic><sub>1</sub> complex decreases <italic>P. aeruginosa</italic> virulence factor production and hinders motility (<xref ref-type="bibr" rid="B88">Shen et&#xa0;al., 2021</xref>). While these reports show a similar trend, the mechanism of <italic>bc</italic><sub>1</sub> virulence regulation has remained unclear until now. In this work, we have shown that elimination of the <italic>bc</italic><sub>1</sub> complex reduces ATP content by 44-92%, which can explain the reduced virulence, as the T3SS is a molecular motor that requires ATP for its function (<xref ref-type="bibr" rid="B35">Hauser, 2009</xref>). Thus, factors that affect energy production should have a direct effect on contact-based virulence. In this report, we extended the studies carried out on invertebrate models by investigating the role of cytochrome <italic>bc</italic><sub>1</sub> in the virulence of <italic>P. aeruginosa</italic> in a clinically-relevant <italic>in vivo</italic> systemic murine infection model. Our results show that while the wild-type strain is highly virulent, producing &gt;80% mortality in less than a week, the PA14 &#x394;<italic>bc</italic><sub>1</sub> strain is completely avirulent, demonstrating the critical role of the enzyme&#x2019;s contribution to <italic>P. aeruginosa</italic> pathogenicity (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3B</bold></xref>).</p>
<p>It has previously been suggested that the highly branched respiratory chain of <italic>P. aeruginosa</italic>, in particular the diversity of terminal oxidases, is advantageous for pathogenicity (<xref ref-type="bibr" rid="B39">Hirai et&#xa0;al., 2016</xref>; <xref ref-type="bibr" rid="B44">Jo et&#xa0;al., 2014</xref>) and survival in different environments, such as biofilms, in which oxygen gradients are established (<xref ref-type="bibr" rid="B45">Jo et&#xa0;al., 2022</xref>). However, our data challenges this hypothesis and shows that cytochrome <italic>bc</italic><sub>1</sub> is the most important respiratory enzyme in most conditions, including planktonic growth in physiologic media, and in biofilms. The critical role of the <italic>bc</italic><sub>1</sub> complex is likely due to its involvement in supporting the activity of the terminal cytochrome <italic>c</italic> oxidases: <italic>caa<sub>3</sub></italic>, <italic>cbb<sub>3</sub></italic>-1, and <italic>cbb<sub>3</sub></italic>-2, which contribute the greatest amount of usable energy for the pathogen under aerobic conditions (<xref ref-type="bibr" rid="B100">Williams et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>; <xref ref-type="bibr" rid="B93">Srivastav et&#xa0;al., 2025</xref>). Indeed, cytochrome <italic>c</italic> oxidases have been reported as essential for <italic>P. aeruginosa</italic> PA14 biofilm and pathogenicity in <italic>Caenorhabditis elegans</italic> (<xref ref-type="bibr" rid="B43">Jo et&#xa0;al., 2017</xref>), as deletion of subunit CcoN4, which makes complexes with <italic>cbb<sub>3</sub>&#x2013;</italic>1 and <italic>cbb<sub>3</sub></italic>-2 (<xref ref-type="bibr" rid="B39">Hirai et&#xa0;al., 2016</xref>), impairs biofilm architecture and improves nematode survival (<xref ref-type="bibr" rid="B43">Jo et&#xa0;al., 2017</xref>). Furthermore, elimination of <italic>bc</italic><sub>1</sub>&#x2019;s Rieske subunit gene has been reported to interfere with the pathogen&#x2019;s PQS, hindering biofilm formation (<xref ref-type="bibr" rid="B92">Soh et&#xa0;al., 2021</xref>). In addition to its critical role in aerobic conditions, the <italic>bc</italic><sub>1</sub> complex also has a fundamental role under anaerobic environments, as it supports cytochrome <italic>c</italic> reduction, which is required for nitrate and nitrite-based anaerobic respiration (<xref ref-type="bibr" rid="B100">Williams et&#xa0;al., 2007</xref>). Taken together, the data strongly support a critical role of the <italic>bc</italic><sub>1</sub> complex in virulence, supporting the bioenergetic pathways of the cell necessary for the survival of the pathogen or the expression or secretion of virulence factors.</p>
</sec>
<sec id="s4_3">
<title>Cytochrome <italic>bc</italic><sub>1</sub> plays critical bioenergetic roles under physiologic conditions</title>
<p>Our data show that in both physiologic conditions, mAUM and LM, the ATP content of wild-type PA14 cells increased 2.4-4.3 times compared to LB, which suggests that the respiratory metabolism is activated. Indeed, we reported that cells grown in mAUM show an increase of about 3 times in the respiratory activity (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>), consistent with the observed increase in ATP content in this condition (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4A</bold></xref>). Based on this result, we propose that the respiratory activity of cells grown in LM could also be activated and that the <italic>bc</italic><sub>1</sub> complex would be even more important in this condition. Our results show that the elimination of cytochrome <italic>bc</italic><sub>1</sub> significantly decreased ATP in the physiologically relevant mAUM and LM media in both growth phases. These results independently corroborate the hypothesis proposed by our group that electron transfer through cytochrome <italic>bc</italic><sub>1</sub> (and the associated terminal oxidases) is the most important energy-generating pathway in <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B58">Liang et&#xa0;al., 2020</xref>). This is also consistent with the enzyme&#x2019;s pumping stoichiometry, as <italic>bc</italic><sub>1</sub> and cytochrome <italic>c</italic> oxidases pump 6 protons through the membrane per electron pair (<xref ref-type="bibr" rid="B67">Mitchell, 2011</xref>), compared to 2 and 4 protons per electron pair for <italic>bd</italic> (<xref ref-type="bibr" rid="B20">D&#x2019;mello et&#xa0;al., 1996</xref>) and <italic>bo<sub>3</sub></italic> (<xref ref-type="bibr" rid="B31">Graf et&#xa0;al., 2019</xref>) oxidases, respectively (<xref ref-type="bibr" rid="B42">Hu et&#xa0;al., 2024</xref>). Interestingly, we found a significant increase in the membrane potential of the mutant compared to the wild-type during logarithmic growth in LM. Membrane potential is a complex metabolic parameter that depends on many factors, including respiratory activity, membrane permeability (regulated by membrane lipid composition), and numerous gradient-consuming processes (ATP synthesis, active transport, motility, etc.). It is likely that due to the limited ability of the respiratory chain to produce a membrane potential, the gradient-consuming steps are significantly downregulated, which would allow the cell to maintain a stable membrane potential but would affect downstream homeostatic processes. However, further experiments are required to clarify this issue.</p>
<p>In addition to the respiratory metabolism, the <italic>bc</italic><sub>1</sub> complex would also impact ROS production by the cell (<xref ref-type="bibr" rid="B13">Borisov et&#xa0;al., 2021</xref>), as this complex is known to be the main contributor within the electron transport chain (<xref ref-type="bibr" rid="B16">Chance and Hollunger, 1960</xref>). Quantification of ROS production demonstrates that the wild-type strain produces significantly more ROS in LB media during both growth phases and LM during stationary phase (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4B</bold></xref>), consistent with this complex as a major source of ROS. However, in mAUM the mutant produced significantly more ROS compared to the wild-type due to accumulation of electrons in the quinol pool, leading to redirection via the <italic>bd</italic> oxidase. Thus, the excess electrons can react with oxygen, generating superoxide, linking the decreased ATP observed by the mutant in mAUM to the observed increase in ROS. Moreover, other reports have shown that mutants lacking <italic>bc</italic><sub>1</sub> do not produce PQS signaling (<xref ref-type="bibr" rid="B92">Soh et&#xa0;al., 2021</xref>), which induces an antioxidant response (<xref ref-type="bibr" rid="B36">H&#xe4;ussler and Becker, 2008</xref>). This deficiency could account for the increase in ROS production in the mutant strain cultured in mAUM in comparison to the wild-type in both growth phases. During the logarithmic phase in LM, there is no significant difference in ROS production between the wild-type and mutant strains, which can be attributed to both being highly metabolically active during these conditions, prioritizing energy and resources for growth. Furthermore, the extended lag phase and reduced growth rate observed in both strains suggests that ROS mechanisms may be more apparent under non-proliferative or stress-inducing conditions.</p>
</sec>
<sec id="s4_4">
<title>Metabolic adaptations of the cytochrome <italic>bc</italic><sub>1</sub> mutant</title>
<p>The data presented here, as well as previous reports in the literature, indicate that the <italic>bc</italic><sub>1</sub> complex is critical but not essential for growth, which suggests that the mutant is able to use other metabolic pathways to compensate for its absence. In this report, we show that the mutant compensates for lack of the <italic>bc</italic><sub>1</sub> complex by using <italic>bd</italic> oxidase, which intriguingly only pumps 2 H<sup>+</sup> per electron pair (<xref ref-type="bibr" rid="B20">D&#x2019;mello et&#xa0;al., 1996</xref>), instead of <italic>bo</italic><sub>3</sub> oxidase, which pumps twice as many protons (<xref ref-type="bibr" rid="B31">Graf et&#xa0;al., 2019</xref>). In addition, the cells shift from NQR, which pumps two cations (Na<sup>+</sup> or protons) per electron pair (<xref ref-type="bibr" rid="B81">Raba et&#xa0;al., 2018</xref>), to NDH-2, which is not a proton pump (<xref ref-type="bibr" rid="B38">Heikal et&#xa0;al., 2014</xref>), as the primary NADH dehydrogenase. Thus, the respiratory chain of the mutant (NDH-2 plus <italic>bd</italic> oxidase) pumps a total of 2 protons per electron pair, while the wild-type chain (NQR, <italic>bc</italic><sub>1</sub>, and cytochrome <italic>c</italic> oxidases) pumps 8 protons per electron pair. Assuming that the metabolic rates through the Krebs cycle are similar in the mutant, this would represent a predicted decrease of 4 times in the ATP production in the <italic>bc</italic><sub>1</sub> mutant, which is close to the observed experimental values. Furthermore, our observations regarding growth behavior may also be attributed to lack of ATP production by the mutant, causing the bacteria to compensate by utilizing fermentation or the ADI pathway (<xref ref-type="bibr" rid="B100">Williams et&#xa0;al., 2007</xref>). This process does not contribute to formation of the proton gradient, and thus may not be enough to sustain virulence. However, in LB media, we did not see a significant difference in ATP production between the wild-type and mutant strains, which may be due to reliance on fermentation or substrate-level phosphorylation. This drastic decrease in ATP production explains a severe decrease in virulence by the mutant cells <italic>in vitro</italic> and an almost complete lack of virulence in the animal model.</p>
</sec>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusions</title>
<p>The findings of this study have deepened our understanding of the metabolic processes employed by <italic>P. aeruginosa</italic> in two physiologically relevant conditions: the lung and urinary tract environments. Our data have demonstrated that cytochrome <italic>bc</italic><sub>1</sub> is a promising therapeutic target and that the elimination of this enzyme significantly hinders bacterial growth, virulence, pathogenicity, and energy generation. These results indicate that cytochrome <italic>bc</italic><sub>1</sub> plays a fundamental role in the production of the proton gradient, which sustains ATP synthesis (<xref ref-type="bibr" rid="B67">Mitchell, 2011</xref>) and all nutrient transport activities. To compensate for the cytochrome <italic>bc</italic><sub>1</sub> mutation, <italic>P. aeruginosa</italic> subsequently adapts its metabolism by switching to NDH-2 and <italic>bd</italic>-type terminal oxidase, which support growth but do not sustain a substantial energy metabolism that allows the production of virulence factors. These findings validate cytochrome <italic>bc</italic><sub>1</sub> as a possible drug target in <italic>P. aeruginosa</italic> and shed light on the significance of oxidative phosphorylation in virulence and pathogenicity in these diverse environments. Taken together, these data provide valuable insight into potential treatment methodologies that can be implemented to treat this multidrug-resistant pathogen, including targeting the <italic>bc</italic><sub>1</sub> complex with antivirulence molecules. Impairing the pathogen&#x2019;s metabolism through cytochrome <italic>bc</italic><sub>1</sub> inhibition would produce a strong reduction in virulence factor production, which may limit disease progression while reducing the selective pressure that drives drug resistance as cytochrome <italic>bc</italic><sub>1</sub> is not essential for growth, offering a viable alternative to treat infections produced by this highly relevant pathogen.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.</p></sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The animal study was approved by Institutional Animal Care and Use Committee (IACUC) at the Illinois Institute of Technology, <email xlink:href="mailto:iacuc@illinoistech.edu">iacuc@illinoistech.edu</email>. The study was conducted in accordance with the local legislation and institutional requirements.</p></sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>JS: Conceptualization, Writing &#x2013; review &amp; editing, Investigation, Validation, Writing &#x2013; original draft, Visualization, Data curation, Formal Analysis, Methodology. MG-AM: Formal Analysis, Writing &#x2013; original draft, Investigation, Writing &#x2013; review &amp; editing, Methodology, Visualization. NP: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing, Formal Analysis, Investigation. GB: Writing &#x2013; review &amp; editing, Investigation. SA: Writing &#x2013; review &amp; editing, Investigation. KT: Resources, Writing &#x2013; original draft, Formal Analysis, Funding acquisition, Project administration, Methodology, Conceptualization, Writing &#x2013; review &amp; editing, Supervision, Validation, Investigation. OJ: Project administration, Conceptualization, Writing &#x2013; review &amp; editing, Supervision, Validation, Writing &#x2013; original draft, Formal Analysis, Funding acquisition, Resources, Methodology, Visualization.</p></sec>
<ack>
<title>Acknowledgments</title>
<p>We thank Dr. Siryaporn at University of California, Irvine for generously providing the pAS03 and pUCP18-RedS plasmids and for sharing transformation protocols.</p>
</ack>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Abramoff</surname> <given-names>M. D.</given-names></name>
<name><surname>Magalh&#xe3;es</surname> <given-names>P. J.</given-names></name>
<name><surname>Ram</surname> <given-names>S. J.</given-names></name>
</person-group> (<year>2004</year>). 
<article-title>Image processing with imageJ</article-title>. <source>Biophotonics Int.</source> <volume>11</volume>, <fpage>36</fpage>&#x2013;<lpage>42</lpage>.
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Alvarez-Ortega</surname> <given-names>C.</given-names></name>
<name><surname>Harwood</surname> <given-names>C. S.</given-names></name>
</person-group> (<year>2007</year>). 
<article-title>Responses of <italic>Pseudomonas aeruginosa</italic> to low oxygen indicate that growth in the cystic fibrosis lung is by aerobic respiration</article-title>. <source>Mol. Microbiol.</source> <volume>65</volume>, <fpage>153</fpage>&#x2013;<lpage>165</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1365-2958.2007.05772.x</pub-id>, PMID: <pub-id pub-id-type="pmid">17581126</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Arai</surname> <given-names>H.</given-names></name>
</person-group> (<year>2011</year>). 
<article-title>Regulation and function of versatile aerobic and anaerobic respiratory metabolism in <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Front. Microbiol.</source> <volume>2</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmicb.2011.00103</pub-id>, PMID: <pub-id pub-id-type="pmid">21833336</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Arai</surname> <given-names>H.</given-names></name>
<name><surname>Kawakami</surname> <given-names>T.</given-names></name>
<name><surname>Osamura</surname> <given-names>T.</given-names></name>
<name><surname>Hirai</surname> <given-names>T.</given-names></name>
<name><surname>Sakai</surname> <given-names>Y.</given-names></name>
<name><surname>Ishii</surname> <given-names>M.</given-names></name>
</person-group> (<year>2014</year>). 
<article-title>Enzymatic characterization and <italic>in vivo</italic> function of five terminal oxidases in <italic>Pseudomonas aeruginosa</italic></article-title>. <source>J. Bacteriol.</source> <volume>196</volume>, <fpage>4206</fpage>&#x2013;<lpage>4215</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/JB.02176-14</pub-id>, PMID: <pub-id pub-id-type="pmid">25182500</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ashworth</surname> <given-names>E. A.</given-names></name>
<name><surname>Wright</surname> <given-names>R. C. T.</given-names></name>
<name><surname>Shears</surname> <given-names>R. K.</given-names></name>
<name><surname>Wong</surname> <given-names>J. K. L.</given-names></name>
<name><surname>Hassan</surname> <given-names>A.</given-names></name>
<name><surname>Hall</surname> <given-names>J. P. J.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>Exploiting lung adaptation and phage steering to clear pan-resistant <italic>Pseudomonas aeruginosa</italic> infections in <italic>vivo</italic></article-title>. <source>Nat. Commun.</source> <volume>15</volume>, <fpage>1547</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-024-45785-z</pub-id>, PMID: <pub-id pub-id-type="pmid">38378698</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="book">(<year>2022</year>). <source>COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022</source> (<publisher-loc>Atlanta GA, USA</publisher-loc>: 
<publisher-name>Centers for Disease Control and Prevention</publisher-name>). doi:&#xa0;<pub-id pub-id-type="doi">10.15620/cdc:117915</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="book">(<year>2022</year>). <source>Multidrug-resistant <italic>Pseudomonas aeruginosa</italic></source> (<publisher-loc>Atlanta GA, USA</publisher-loc>: 
<publisher-name>Centers for Disease Control and Prevention</publisher-name>).
</mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="book">(<year>2024</year>). <source>WHO Bacterial Priority Pathogens List 2024: Bacterial Pathogens of Public Health Importance, to Guide Research, Development, and Strategies to Prevent and Control Antimicrobial Resistance</source>. <edition>1st ed</edition> (<publisher-loc>Geneva</publisher-loc>: 
<publisher-name>World Health Organization</publisher-name>).
</mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Baggish</surname> <given-names>A. L.</given-names></name>
<name><surname>Hill</surname> <given-names>D. R.</given-names></name>
</person-group> (<year>2002</year>). 
<article-title>Antiparasitic agent atovaquone</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>46</volume>, <fpage>1163</fpage>&#x2013;<lpage>1173</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/AAC.46.5.1163-1173.2002</pub-id>, PMID: <pub-id pub-id-type="pmid">11959541</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Barth</surname> <given-names>A. L.</given-names></name>
<name><surname>Pitt</surname> <given-names>T. L.</given-names></name>
</person-group> (<year>1996</year>). 
<article-title>The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic <italic>Pseudomonas aeruginosa</italic></article-title>. <source>J. Med. Microbiol.</source> <volume>45</volume>, <fpage>110</fpage>&#x2013;<lpage>119</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1099/00222615-45-2-110</pub-id>, PMID: <pub-id pub-id-type="pmid">8683546</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bassetti</surname> <given-names>M.</given-names></name>
<name><surname>Rello</surname> <given-names>J.</given-names></name>
<name><surname>Blasi</surname> <given-names>F.</given-names></name>
<name><surname>Goossens</surname> <given-names>H.</given-names></name>
<name><surname>Sotgiu</surname> <given-names>G.</given-names></name>
<name><surname>Tavoschi</surname> <given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>2020</year>). 
<article-title>Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections</article-title>. <source>Int. J. Antimicrob. Agents</source> <volume>56</volume>, <elocation-id>106184</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106184</pub-id>, PMID: <pub-id pub-id-type="pmid">33045353</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Berger</surname> <given-names>A.</given-names></name>
<name><surname>Dohnt</surname> <given-names>K.</given-names></name>
<name><surname>Tielen</surname> <given-names>P.</given-names></name>
<name><surname>Jahn</surname> <given-names>D.</given-names></name>
<name><surname>Becker</surname> <given-names>J.</given-names></name>
<name><surname>Wittmann</surname> <given-names>C.</given-names></name>
</person-group> (<year>2014</year>). 
<article-title>Robustness and Plasticity of Metabolic Pathway Flux among Uropathogenic Isolates of <italic>Pseudomonas aeruginosa</italic></article-title>. <source>PloS One</source> <volume>9</volume>, <fpage>e88368</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0088368</pub-id>, PMID: <pub-id pub-id-type="pmid">24709961</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Borisov</surname> <given-names>V. B.</given-names></name>
<name><surname>Siletsky</surname> <given-names>S. A.</given-names></name>
<name><surname>Nastasi</surname> <given-names>M. R.</given-names></name>
<name><surname>Forte</surname> <given-names>E.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>ROS defense systems and terminal oxidases in bacteria</article-title>. <source>Antioxidants</source> <volume>10</volume>, <elocation-id>839</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/antiox10060839</pub-id>, PMID: <pub-id pub-id-type="pmid">34073980</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Brand</surname> <given-names>M. D.</given-names></name>
</person-group> (<year>2016</year>). 
<article-title>Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling</article-title>. <source>Free Radical Biol. Med. Mitochondrial Redox Signaling Health Dis.</source> <volume>100</volume>, <fpage>14</fpage>&#x2013;<lpage>31</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.04.001</pub-id>, PMID: <pub-id pub-id-type="pmid">27085844</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bru</surname> <given-names>J.-L.</given-names></name>
<name><surname>Rawson</surname> <given-names>B.</given-names></name>
<name><surname>Trinh</surname> <given-names>C.</given-names></name>
<name><surname>Whiteson</surname> <given-names>K.</given-names></name>
<name><surname>H&#xf8;yland-Kroghsbo</surname> <given-names>N. M.</given-names></name>
<name><surname>Siryaporn</surname> <given-names>A.</given-names></name>
</person-group> (<year>2019</year>). 
<article-title>PQS produced by the <italic>Pseudomonas aeruginosa</italic> stress response repels swarms away from bacteriophage and antibiotics</article-title>. <source>J. Bacteriol.</source> <volume>201</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/JB.00383-19</pub-id>, PMID: <pub-id pub-id-type="pmid">31451543</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chance</surname> <given-names>B.</given-names></name>
<name><surname>Hollunger</surname> <given-names>G.</given-names></name>
</person-group> (<year>1960</year>). 
<article-title>Energy-linked reduction of mitochondrial pyridine nucleotide</article-title>. <source>Nature</source> <volume>185</volume>, <fpage>666</fpage>&#x2013;<lpage>672</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/185666a0</pub-id>, PMID: <pub-id pub-id-type="pmid">13809106</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chmiel</surname> <given-names>J. F.</given-names></name>
<name><surname>Davis</surname> <given-names>P. B.</given-names></name>
</person-group> (<year>2003</year>). 
<article-title>State of the Art: Why do the lungs of patients with cystic fibrosis become infected and why can&#x2019;t they clear the infection</article-title>? <source>Respir. Res.</source> <volume>4</volume>, <elocation-id>8</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1465-9921-4-8</pub-id>, PMID: <pub-id pub-id-type="pmid">14511398</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ciofu</surname> <given-names>O.</given-names></name>
<name><surname>Rojo-Molinero</surname> <given-names>E.</given-names></name>
<name><surname>Maci&#xe0;</surname> <given-names>M. D.</given-names></name>
<name><surname>Oliver</surname> <given-names>A.</given-names></name>
</person-group> (<year>2017</year>). 
<article-title>Antibiotic treatment of biofilm infections</article-title>. <source>APMIS</source> <volume>125</volume>, <fpage>304</fpage>&#x2013;<lpage>319</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/apm.12673</pub-id>, PMID: <pub-id pub-id-type="pmid">28407419</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cole</surname> <given-names>S. J.</given-names></name>
<name><surname>Hall</surname> <given-names>C. L.</given-names></name>
<name><surname>Schniederberend</surname> <given-names>M.</given-names></name>
<name><surname>Farrow</surname> <given-names>J. M.</given-names> <suffix>III</suffix></name>
<name><surname>Goodson</surname> <given-names>J. R.</given-names></name>
<name><surname>Pesci</surname> <given-names>E. C.</given-names></name>
<etal/>
</person-group>. (<year>2018</year>). 
<article-title>Host suppression of quorum sensing during catheter-associated urinary tract infections</article-title>. <source>Nat. Commun.</source> <volume>9</volume>, <fpage>4436</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-018-06882-y</pub-id>, PMID: <pub-id pub-id-type="pmid">30361690</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>D&#x2019;mello</surname> <given-names>R.</given-names></name>
<name><surname>Hill</surname> <given-names>S.</given-names></name>
<name><surname>Poole</surname> <given-names>R. K.</given-names></name>
</person-group> (<year>1996</year>). 
<article-title>The cytochrome bd quinol oxidase in <italic>Escherichia coli</italic> has an extremely high oxygen affinity and two oxygen-binding haems: implications for regulation of activity <italic>in vivo</italic> by oxygen inhibition</article-title>. <source>Microbiol. (Reading)</source> <volume>142</volume>, <fpage>755</fpage>&#x2013;<lpage>763</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1099/00221287-142-4-755</pub-id>, PMID: <pub-id pub-id-type="pmid">8936304</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Daniels</surname> <given-names>C. J.</given-names></name>
<name><surname>Bole</surname> <given-names>D. G.</given-names></name>
<name><surname>Quay</surname> <given-names>S. C.</given-names></name>
<name><surname>Oxender</surname> <given-names>D. L.</given-names></name>
</person-group> (<year>1981</year>). 
<article-title>Role for membrane potential in the secretion of protein into the periplasm of <italic>Escherichia coli.</italic> Proc</article-title>. <source>Natl. Acad. Sci. U.S.A.</source> <volume>78</volume>, <fpage>5396</fpage>&#x2013;<lpage>5400</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.78.9.5396</pub-id>, PMID: <pub-id pub-id-type="pmid">7029533</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Datsenko</surname> <given-names>K. A.</given-names></name>
<name><surname>Wanner</surname> <given-names>B. L.</given-names></name>
</person-group> (<year>2000</year>). 
<article-title>One-step inactivation of chromosomal genes in <italic>Escherichia coli</italic> K-12 using PCR products</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>97</volume>, <fpage>6640</fpage>&#x2013;<lpage>6645</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.120163297</pub-id>, PMID: <pub-id pub-id-type="pmid">10829079</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Degli Esposti</surname> <given-names>M.</given-names></name>
</person-group> (<year>1998</year>). 
<article-title>Inhibitors of NADH-ubiquinone reductase: an overview</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1364</volume>, <fpage>222</fpage>&#x2013;<lpage>235</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0005-2728(98)00029-2</pub-id>, PMID: <pub-id pub-id-type="pmid">9593904</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Diaz</surname> <given-names>M. H.</given-names></name>
<name><surname>Shaver</surname> <given-names>C. M.</given-names></name>
<name><surname>King</surname> <given-names>J. D.</given-names></name>
<name><surname>Musunuri</surname> <given-names>S.</given-names></name>
<name><surname>Kazzaz</surname> <given-names>J. A.</given-names></name>
<name><surname>Hauser</surname> <given-names>A. R.</given-names></name>
</person-group> (<year>2008</year>). 
<article-title><italic>Pseudomonas aeruginosa</italic> Induces Localized Immunosuppression during Pneumonia</article-title>. <source>Infect. Immun.</source> <volume>76</volume>, <fpage>4414</fpage>&#x2013;<lpage>4421</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/IAI.00012-08</pub-id>, PMID: <pub-id pub-id-type="pmid">18663007</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Eid</surname> <given-names>R.</given-names></name>
<name><surname>Dabar</surname> <given-names>G.</given-names></name>
<name><surname>Hanna</surname> <given-names>L.-R.</given-names></name>
<name><surname>Saliba</surname> <given-names>G.</given-names></name>
<name><surname>Riachy</surname> <given-names>M.</given-names></name>
<name><surname>Choucair</surname> <given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2025</year>). 
<article-title>Comparison of antimicrobial resistance in <italic>Pseudomonas aeruginosa</italic> from intensive care and non-intensive care units and its impact on treatment decisions</article-title>. <source>Sci. Rep.</source> <volume>15</volume>, <fpage>11288</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-025-90791-w</pub-id>, PMID: <pub-id pub-id-type="pmid">40175451</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Filloux</surname> <given-names>A.</given-names></name>
</person-group> (<year>2011</year>). 
<article-title>Protein secretion systems in <italic>Pseudomonas aeruginosa</italic>: an essay on diversity, evolution, and function</article-title>. <source>Front. Microbiol.</source> <volume>2</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmicb.2011.00155</pub-id>, PMID: <pub-id pub-id-type="pmid">21811488</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Folkesson</surname> <given-names>A.</given-names></name>
<name><surname>Jelsbak</surname> <given-names>L.</given-names></name>
<name><surname>Yang</surname> <given-names>L.</given-names></name>
<name><surname>Johansen</surname> <given-names>H. K.</given-names></name>
<name><surname>Ciofu</surname> <given-names>O.</given-names></name>
<name><surname>H&#xf8;iby</surname> <given-names>N.</given-names></name>
<etal/>
</person-group>. (<year>2012</year>). 
<article-title>Adaptation of <italic>Pseudomonas aeruginosa</italic> to the cystic fibrosis airway: an evolutionary perspective</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>10</volume>, <fpage>841</fpage>&#x2013;<lpage>851</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrmicro2907</pub-id>, PMID: <pub-id pub-id-type="pmid">23147702</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fraser-Pitt</surname> <given-names>D. J.</given-names></name>
<name><surname>Mercer</surname> <given-names>D. K.</given-names></name>
<name><surname>Smith</surname> <given-names>D.</given-names></name>
<name><surname>Kowalczuk</surname> <given-names>A.</given-names></name>
<name><surname>Robertson</surname> <given-names>J.</given-names></name>
<name><surname>Lovie</surname> <given-names>E.</given-names></name>
<etal/>
</person-group>. (<year>2018</year>). 
<article-title>Cysteamine, an Endogenous Aminothiol, and Cystamine, the Disulfide Product of Oxidation, Increase <italic>Pseudomonas aeruginosa</italic> Sensitivity to Reactive Oxygen and Nitrogen Species and Potentiate Therapeutic Antibiotics against Bacterial Infection</article-title>. <source>Infect. Immun.</source> <volume>86</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/iai.00947-17</pub-id>, PMID: <pub-id pub-id-type="pmid">29581193</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Giuffr&#xe8;</surname> <given-names>A.</given-names></name>
<name><surname>Borisov</surname> <given-names>V. B.</given-names></name>
<name><surname>Arese</surname> <given-names>M.</given-names></name>
<name><surname>Sarti</surname> <given-names>P.</given-names></name>
<name><surname>Forte</surname> <given-names>E.</given-names></name>
</person-group> (<year>2014</year>). 
<article-title>Cytochrome bd oxidase and bacterial tolerance to oxidative and nitrosative stress</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1837</volume>, <fpage>1178</fpage>&#x2013;<lpage>1187</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbabio.2014.01.016</pub-id>, PMID: <pub-id pub-id-type="pmid">24486503</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gonz&#xe1;lez-Montalvo</surname> <given-names>M. A.</given-names></name>
<name><surname>Sorescu</surname> <given-names>J. M.</given-names></name>
<name><surname>Baltes</surname> <given-names>G.</given-names></name>
<name><surname>Ju&#xe1;rez</surname> <given-names>O.</given-names></name>
<name><surname>Tuz</surname> <given-names>K.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title>The respiratory chain of <italic>Klebsiella aerogenes</italic> in urine-like conditions: critical roles of NDH-2 and bd-terminal oxidases</article-title>. <source>Front. Microbiol.</source> <volume>15</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmicb.2024.1479714</pub-id>, PMID: <pub-id pub-id-type="pmid">39568993</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Graf</surname> <given-names>S.</given-names></name>
<name><surname>Brzezinski</surname> <given-names>P.</given-names></name>
<name><surname>von Ballmoos</surname> <given-names>C.</given-names></name>
</person-group> (<year>2019</year>). 
<article-title>The proton pumping bo oxidase from <italic>Vitreoscilla</italic></article-title>. <source>Sci. Rep.</source> <volume>9</volume>, <fpage>4766</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-019-40723-2</pub-id>, PMID: <pub-id pub-id-type="pmid">30886219</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Harrison</surname> <given-names>E. M.</given-names></name>
<name><surname>Carter</surname> <given-names>M. E. K.</given-names></name>
<name><surname>Luck</surname> <given-names>S.</given-names></name>
<name><surname>Ou</surname> <given-names>H.-Y.</given-names></name>
<name><surname>He</surname> <given-names>X.</given-names></name>
<name><surname>Deng</surname> <given-names>Z.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>). 
<article-title>Pathogenicity islands PAPI-1 and PAPI-2 contribute individually and synergistically to the virulence of <italic>pseudomonas aeruginosa</italic> strain PA14</article-title>. <source>Infect. Immun.</source> <volume>78</volume>, <fpage>1437</fpage>&#x2013;<lpage>1446</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/IAI.00621-09</pub-id>, PMID: <pub-id pub-id-type="pmid">20123716</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hasegawa</surname> <given-names>N.</given-names></name>
<name><surname>Arai</surname> <given-names>H.</given-names></name>
<name><surname>Igarashi</surname> <given-names>Y.</given-names></name>
</person-group> (<year>2003</year>). 
<article-title>Need for Cytochrome bc1 Complex for Dissimilatory Nitrite Reduction of <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Biosci. Biotechnol. Biochem.</source> <volume>67</volume>, <fpage>121</fpage>&#x2013;<lpage>126</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1271/bbb.67.121</pub-id>, PMID: <pub-id pub-id-type="pmid">12619683</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hassett</surname> <given-names>D. J.</given-names></name>
<name><surname>Cuppoletti</surname> <given-names>J.</given-names></name>
<name><surname>Trapnell</surname> <given-names>B.</given-names></name>
<name><surname>Lymar</surname> <given-names>S. V.</given-names></name>
<name><surname>Rowe</surname> <given-names>J. J.</given-names></name>
<name><surname>Sun Yoon</surname> <given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>). 
<article-title>Anaerobic metabolism and quorum sensing by <italic>Pseudomonas aeruginosa</italic> biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets</article-title>. <source>Adv. Drug Deliv. Rev. Curr. Concepts Pathophysiol. Drug Dev. Cystic Fibrosis</source> <volume>54</volume>, <fpage>1425</fpage>&#x2013;<lpage>1443</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0169-409X(02)00152-7</pub-id>, PMID: <pub-id pub-id-type="pmid">12458153</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hauser</surname> <given-names>A. R.</given-names></name>
</person-group> (<year>2009</year>). 
<article-title>The type III secretion system of <italic>Pseudomonas aeruginosa</italic>: infection by injection</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>7</volume>, <fpage>654</fpage>&#x2013;<lpage>665</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrmicro2199</pub-id>, PMID: <pub-id pub-id-type="pmid">19680249</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>H&#xe4;ussler</surname> <given-names>S.</given-names></name>
<name><surname>Becker</surname> <given-names>T.</given-names></name>
</person-group> (<year>2008</year>). 
<article-title>The pseudomonas quinolone signal (PQS) balances life and death in <italic>Pseudomonas aeruginosa</italic> populations</article-title>. <source>PloS Pathog.</source> <volume>4</volume>, <fpage>e1000166</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1000166</pub-id>, PMID: <pub-id pub-id-type="pmid">18818733</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>He</surname> <given-names>J.</given-names></name>
<name><surname>Baldini</surname> <given-names>R. L.</given-names></name>
<name><surname>D&#xe9;ziel</surname> <given-names>E.</given-names></name>
<name><surname>Saucier</surname> <given-names>M.</given-names></name>
<name><surname>Zhang</surname> <given-names>Q.</given-names></name>
<name><surname>Liberati</surname> <given-names>N. T.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>). 
<article-title>The broad host range pathogen <italic>Pseudomonas aeruginosa</italic> strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>101</volume>, <fpage>2530</fpage>&#x2013;<lpage>2535</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0304622101</pub-id>, PMID: <pub-id pub-id-type="pmid">14983043</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Heikal</surname> <given-names>A.</given-names></name>
<name><surname>Nakatani</surname> <given-names>Y.</given-names></name>
<name><surname>Dunn</surname> <given-names>E.</given-names></name>
<name><surname>Weimar</surname> <given-names>M. R.</given-names></name>
<name><surname>Day</surname> <given-names>C. L.</given-names></name>
<name><surname>Baker</surname> <given-names>E. N.</given-names></name>
<etal/>
</person-group>. (<year>2014</year>). 
<article-title>Structure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generation</article-title>. <source>Mol. Microbiol.</source> <volume>91</volume>, <fpage>950</fpage>&#x2013;<lpage>964</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/mmi.12507</pub-id>, PMID: <pub-id pub-id-type="pmid">24444429</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hirai</surname> <given-names>T.</given-names></name>
<name><surname>Osamura</surname> <given-names>T.</given-names></name>
<name><surname>Ishii</surname> <given-names>M.</given-names></name>
<name><surname>Arai</surname> <given-names>H.</given-names></name>
</person-group> (<year>2016</year>). 
<article-title>Expression of multiple cbb3 cytochrome c oxidase isoforms by combinations of multiple isosubunits in <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>113</volume>, <fpage>12815</fpage>&#x2013;<lpage>12819</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1613308113</pub-id>, PMID: <pub-id pub-id-type="pmid">27791152</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hoboth</surname> <given-names>C.</given-names></name>
<name><surname>Hoffmann</surname> <given-names>R.</given-names></name>
<name><surname>Eichner</surname> <given-names>A.</given-names></name>
<name><surname>Henke</surname> <given-names>C.</given-names></name>
<name><surname>Schmoldt</surname> <given-names>S.</given-names></name>
<name><surname>Imhof</surname> <given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>). 
<article-title>Dynamics of adaptive microevolution of hypermutable <italic>Pseudomonas aeruginosa</italic> during chronic pulmonary infection in patients with cystic fibrosis</article-title>. <source>J. Infect. Dis.</source> <volume>200</volume>, <fpage>118</fpage>&#x2013;<lpage>130</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1086/599360</pub-id>, PMID: <pub-id pub-id-type="pmid">19459782</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Hogardt</surname> <given-names>M.</given-names></name>
<name><surname>Heesemann</surname> <given-names>J.</given-names></name>
</person-group> (<year>2013</year>). &#x201c;
<article-title>Microevolution of <italic>Pseudomonas aeruginosa</italic> to a chronic pathogen of the cystic fibrosis lung</article-title>,&#x201d; in <source>Between Pathogenicity and Commensalism</source>. Eds. 
<person-group person-group-type="editor">
<name><surname>Dobrindt</surname> <given-names>U.</given-names></name>
<name><surname>Hacker</surname> <given-names>J. H.</given-names></name>
<name><surname>Svanborg</surname> <given-names>C.</given-names></name>
</person-group> (
<publisher-name>Springer, Berlin</publisher-name>, <publisher-loc>Heidelberg</publisher-loc>), <fpage>91</fpage>&#x2013;<lpage>118</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/82_2011_199</pub-id>, PMID: <pub-id pub-id-type="pmid">22311171</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname> <given-names>Y.</given-names></name>
<name><surname>Yuan</surname> <given-names>M.</given-names></name>
<name><surname>Julian</surname> <given-names>A.</given-names></name>
<name><surname>Tuz</surname> <given-names>K.</given-names></name>
<name><surname>Ju&#xe1;rez</surname> <given-names>O.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title>Identification of complex III, NQR, and SDH as primary bioenergetic enzymes during the stationary phase of <italic>Pseudomonas aeruginosa</italic> cultured in urine-like conditions</article-title>. <source>Front. Microbiol.</source> <volume>15</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmicb.2024.1347466</pub-id>, PMID: <pub-id pub-id-type="pmid">38468849</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jo</surname> <given-names>J.</given-names></name>
<name><surname>Cortez</surname> <given-names>K. L.</given-names></name>
<name><surname>Cornell</surname> <given-names>W. C.</given-names></name>
<name><surname>Price-Whelan</surname> <given-names>A.</given-names></name>
<name><surname>Dietrich</surname> <given-names>L. E.</given-names></name>
</person-group> (<year>2017</year>). 
<article-title>An orphan cbb3-type cytochrome oxidase subunit supports <italic>Pseudomonas aeruginosa</italic> biofilm growth and virulence</article-title>. <source>eLife</source> <volume>6</volume>, <fpage>e30205</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.7554/eLife.30205</pub-id>, PMID: <pub-id pub-id-type="pmid">29160206</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jo</surname> <given-names>J.</given-names></name>
<name><surname>Price-Whelan</surname> <given-names>A.</given-names></name>
<name><surname>Dietrich</surname> <given-names>L. E. P.</given-names></name>
</person-group> (<year>2014</year>). 
<article-title>An aerobic exercise: defining the roles of <italic>Pseudomonas aeruginosa</italic> terminal oxidases</article-title>. <source>J. Bacteriol.</source> <volume>196</volume>, <fpage>4203</fpage>&#x2013;<lpage>4205</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/JB.02336-14</pub-id>, PMID: <pub-id pub-id-type="pmid">25266389</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jo</surname> <given-names>J.</given-names></name>
<name><surname>Price-Whelan</surname> <given-names>A.</given-names></name>
<name><surname>Dietrich</surname> <given-names>L. E. P.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Gradients and consequences of heterogeneity in biofilms</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>20</volume>, <fpage>593</fpage>&#x2013;<lpage>607</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41579-022-00692-2</pub-id>, PMID: <pub-id pub-id-type="pmid">35149841</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kahm</surname> <given-names>M.</given-names></name>
<name><surname>Hasenbrink</surname> <given-names>G.</given-names></name>
<name><surname>Lichtenberg-Frat&#xe9;</surname> <given-names>H.</given-names></name>
<name><surname>Ludwig</surname> <given-names>J.</given-names></name>
<name><surname>Kschischo</surname> <given-names>M.</given-names></name>
</person-group> (<year>2010</year>). 
<article-title>grofit: fitting biological growth curves with R</article-title>. <source>J. Stat. Softw.</source> <volume>33</volume>, <fpage>1</fpage>&#x2013;<lpage>21</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.18637/jss.v033.i07</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kamal</surname> <given-names>S.</given-names></name>
<name><surname>Varshney</surname> <given-names>K.</given-names></name>
<name><surname>Uayan</surname> <given-names>D. J.</given-names></name>
<name><surname>Tenorio</surname> <given-names>B. G.</given-names></name>
<name><surname>Pillay</surname> <given-names>P.</given-names></name>
<name><surname>Sava</surname> <given-names>S. T.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title>Risk factors and clinical characteristics of pandrug-resistant <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Cureus</source> <volume>16</volume>, <fpage>e58114</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.7759/cureus.58114</pub-id>, PMID: <pub-id pub-id-type="pmid">38738125</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kazmierczak</surname> <given-names>B. I.</given-names></name>
<name><surname>Engel</surname> <given-names>J. N.</given-names></name>
</person-group> (<year>2002</year>). 
<article-title><italic>Pseudomonas aeruginosa</italic> ExoT acts <italic>in vivo</italic> as a GTPase-activating protein for RhoA, Rac1, and Cdc42</article-title>. <source>Infect. Immun.</source> <volume>70</volume>, <fpage>2198</fpage>&#x2013;<lpage>2205</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/iai.70.4.2198-2205.2002</pub-id>, PMID: <pub-id pub-id-type="pmid">11895987</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>K&#xf5;ressaar</surname> <given-names>T.</given-names></name>
<name><surname>Lepamets</surname> <given-names>M.</given-names></name>
<name><surname>Kaplinski</surname> <given-names>L.</given-names></name>
<name><surname>Raime</surname> <given-names>K.</given-names></name>
<name><surname>Andreson</surname> <given-names>R.</given-names></name>
<name><surname>Remm</surname> <given-names>M.</given-names></name>
</person-group> (<year>2018</year>). 
<article-title>Primer3_masker: integrating masking of template sequence with primer design software</article-title>. <source>Bioinformatics</source> <volume>34</volume>, <fpage>1937</fpage>&#x2013;<lpage>1938</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/bioinformatics/bty036</pub-id>, PMID: <pub-id pub-id-type="pmid">29360956</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Koressaar</surname> <given-names>T.</given-names></name>
<name><surname>Remm</surname> <given-names>M.</given-names></name>
</person-group> (<year>2007</year>). 
<article-title>Enhancements and modifications of primer design program Primer3</article-title>. <source>Bioinformatics</source> <volume>23</volume>, <fpage>1289</fpage>&#x2013;<lpage>1291</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/bioinformatics/btm091</pub-id>, PMID: <pub-id pub-id-type="pmid">17379693</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Krall</surname> <given-names>R.</given-names></name>
<name><surname>Schmidt</surname> <given-names>G.</given-names></name>
<name><surname>Aktories</surname> <given-names>K.</given-names></name>
<name><surname>Barbieri</surname> <given-names>J. T.</given-names></name>
</person-group> (<year>2000</year>). 
<article-title><italic>Pseudomonas aeruginosa</italic> ExoT is a rho GTPase-activating protein</article-title>. <source>Infect. Immun.</source> <volume>68</volume>, <fpage>6066</fpage>&#x2013;<lpage>6068</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/iai.68.10.6066-6068.2000</pub-id>, PMID: <pub-id pub-id-type="pmid">10992524</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kunz Coyne</surname> <given-names>A. J.</given-names></name>
<name><surname>El Ghali</surname> <given-names>A.</given-names></name>
<name><surname>Holger</surname> <given-names>D.</given-names></name>
<name><surname>Rebold</surname> <given-names>N.</given-names></name>
<name><surname>Rybak</surname> <given-names>M. J.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Therapeutic strategies for emerging multidrug-resistant <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Infect. Dis. Ther.</source> <volume>11</volume>, <fpage>661</fpage>&#x2013;<lpage>682</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s40121-022-00591-2</pub-id>, PMID: <pub-id pub-id-type="pmid">35150435</pub-id>
</mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Landry</surname> <given-names>R. M.</given-names></name>
<name><surname>An</surname> <given-names>D.</given-names></name>
<name><surname>Hupp</surname> <given-names>J. T.</given-names></name>
<name><surname>Singh</surname> <given-names>P. K.</given-names></name>
<name><surname>Parsek</surname> <given-names>M. R.</given-names></name>
</person-group> (<year>2006</year>). 
<article-title>Mucin&#x2013;<italic>Pseudomonas aeruginosa</italic> interactions promote biofilm formation and antibiotic resistance</article-title>. <source>Mol. Microbiol.</source> <volume>59</volume>, <fpage>142</fpage>&#x2013;<lpage>151</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1365-2958.2005.04941.x</pub-id>, PMID: <pub-id pub-id-type="pmid">16359324</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>La Rosa</surname> <given-names>R.</given-names></name>
<name><surname>Johansen</surname> <given-names>H. K.</given-names></name>
<name><surname>Molin</surname> <given-names>S.</given-names></name>
</person-group> (<year>2018</year>). 
<article-title>Convergent Metabolic Specialization through Distinct Evolutionary Paths in <italic>Pseudomonas aeruginosa</italic></article-title>. <source>mBio</source> <volume>9</volume>, <fpage>e00269</fpage>&#x2013;<lpage>e00218</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/mBio.00269-18</pub-id>, PMID: <pub-id pub-id-type="pmid">29636437</pub-id>
</mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>La Rosa</surname> <given-names>R.</given-names></name>
<name><surname>Johansen</surname> <given-names>H. K.</given-names></name>
<name><surname>Molin</surname> <given-names>S.</given-names></name>
</person-group> (<year>2019</year>). 
<article-title>Adapting to the Airways: Metabolic Requirements of <italic>Pseudomonas aeruginosa</italic> during the Infection of Cystic Fibrosis Patients</article-title>. <source>Metabolites</source> <volume>9</volume>, <elocation-id>234</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/metabo9100234</pub-id>, PMID: <pub-id pub-id-type="pmid">31623245</pub-id>
</mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname> <given-names>V. T.</given-names></name>
<name><surname>Smith</surname> <given-names>R. S.</given-names></name>
<name><surname>T&#xfc;mmler</surname> <given-names>B.</given-names></name>
<name><surname>Lory</surname> <given-names>S.</given-names></name>
</person-group> (<year>2005</year>). 
<article-title>Activities of <italic>Pseudomonas aeruginosa</italic> Effectors Secreted by the Type III Secretion System <italic>In Vitro</italic> and during Infection</article-title>. <source>Infect. Immun.</source> <volume>73</volume>, <fpage>1695</fpage>&#x2013;<lpage>1705</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/iai.73.3.1695-1705.2005</pub-id>, PMID: <pub-id pub-id-type="pmid">15731070</pub-id>
</mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lesic</surname> <given-names>B.</given-names></name>
<name><surname>Rahme</surname> <given-names>L. G.</given-names></name>
</person-group> (<year>2008</year>). 
<article-title>Use of the lambda Red recombinase system to rapidly generate mutants in <italic>Pseudomonas aeruginosa</italic></article-title>. <source>BMC Mol. Biol.</source> <volume>9</volume>, <elocation-id>20</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1471-2199-9-20</pub-id>, PMID: <pub-id pub-id-type="pmid">18248677</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liang</surname> <given-names>P.</given-names></name>
<name><surname>Fang</surname> <given-names>X.</given-names></name>
<name><surname>Hu</surname> <given-names>Y.</given-names></name>
<name><surname>Yuan</surname> <given-names>M.</given-names></name>
<name><surname>Raba</surname> <given-names>D. A.</given-names></name>
<name><surname>Ding</surname> <given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2020</year>). 
<article-title>The aerobic respiratory chain of <italic>Pseudomonas aeruginosa</italic> cultured in artificial urine media: Role of NQR and terminal oxidases</article-title>. <source>PloS One</source> <volume>15</volume>, <fpage>e0231965</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0231965</pub-id>, PMID: <pub-id pub-id-type="pmid">32324772</pub-id>
</mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liberati</surname> <given-names>N. T.</given-names></name>
<name><surname>Urbach</surname> <given-names>J. M.</given-names></name>
<name><surname>Miyata</surname> <given-names>S.</given-names></name>
<name><surname>Lee</surname> <given-names>D. G.</given-names></name>
<name><surname>Drenkard</surname> <given-names>E.</given-names></name>
<name><surname>Wu</surname> <given-names>G.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>). 
<article-title>An ordered, nonredundant library of <italic>Pseudomonas aeruginosa</italic> strain PA14 transposon insertion mutants</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>103</volume>, <fpage>2833</fpage>&#x2013;<lpage>2838</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0511100103</pub-id>, PMID: <pub-id pub-id-type="pmid">16477005</pub-id>
</mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Livak</surname> <given-names>K. J.</given-names></name>
<name><surname>Schmittgen</surname> <given-names>T. D.</given-names></name>
</person-group> (<year>2001</year>). 
<article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2&#x2013;&#x394;&#x394;CT method</article-title>. <source>Methods</source> <volume>25</volume>, <fpage>402</fpage>&#x2013;<lpage>408</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>, PMID: <pub-id pub-id-type="pmid">11846609</pub-id>
</mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lyczak</surname> <given-names>J. B.</given-names></name>
<name><surname>Cannon</surname> <given-names>C. L.</given-names></name>
<name><surname>Pier</surname> <given-names>G. B.</given-names></name>
</person-group> (<year>2000</year>). 
<article-title>Establishment of <italic>Pseudomonas aeruginosa</italic> infection: lessons from a versatile opportunist</article-title>. <source>Microbes Infect.</source> <volume>2</volume>, <fpage>1051</fpage>&#x2013;<lpage>1060</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s1286-4579(00)01259-4</pub-id>, PMID: <pub-id pub-id-type="pmid">10967285</pub-id>
</mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mancuso</surname> <given-names>G.</given-names></name>
<name><surname>Midiri</surname> <given-names>A.</given-names></name>
<name><surname>Gerace</surname> <given-names>E.</given-names></name>
<name><surname>Marra</surname> <given-names>M.</given-names></name>
<name><surname>Zummo</surname> <given-names>S.</given-names></name>
<name><surname>Biondo</surname> <given-names>C.</given-names></name>
</person-group> (<year>2023</year>). 
<article-title>Urinary tract infections: the current scenario and future prospects</article-title>. <source>Pathogens</source> <volume>12</volume>, <elocation-id>623</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pathogens12040623</pub-id>, PMID: <pub-id pub-id-type="pmid">37111509</pub-id>
</mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Matsushita</surname> <given-names>K.</given-names></name>
<name><surname>Ohnishi</surname> <given-names>T.</given-names></name>
<name><surname>Kaback</surname> <given-names>H. R.</given-names></name>
</person-group> (<year>1987</year>). 
<article-title>NADH-ubiquinone oxidoreductases of the <italic>Escherichia coli</italic> aerobic respiratory chain</article-title>. <source>Biochemistry</source> <volume>26</volume>, <fpage>7732</fpage>&#x2013;<lpage>7737</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/bi00398a029</pub-id>, PMID: <pub-id pub-id-type="pmid">3122832</pub-id>
</mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Maurice</surname> <given-names>N. M.</given-names></name>
<name><surname>Bedi</surname> <given-names>B.</given-names></name>
<name><surname>Sadikot</surname> <given-names>R. T.</given-names></name>
</person-group> (<year>2018</year>). 
<article-title><italic>Pseudomonas aeruginosa</italic> biofilms: host response and clinical implications in lung infections</article-title>. <source>Am. J. Respir. Cell Mol. Biol.</source> <volume>58</volume>, <fpage>428</fpage>&#x2013;<lpage>439</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1165/rcmb.2017-0321TR</pub-id>, PMID: <pub-id pub-id-type="pmid">29372812</pub-id>
</mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mikkelsen</surname> <given-names>H.</given-names></name>
<name><surname>McMullan</surname> <given-names>R.</given-names></name>
<name><surname>Filloux</surname> <given-names>A.</given-names></name>
</person-group> (<year>2011</year>). 
<article-title>The <italic>Pseudomonas aeruginosa</italic> reference strain PA14 displays increased virulence due to a mutation in ladS</article-title>. <source>PloS One</source> <volume>6</volume>, <fpage>e29113</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0029113</pub-id>, PMID: <pub-id pub-id-type="pmid">22216178</pub-id>
</mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Miranda</surname> <given-names>S. W.</given-names></name>
<name><surname>Asfahl</surname> <given-names>K. L.</given-names></name>
<name><surname>Dandekar</surname> <given-names>A. A.</given-names></name>
<name><surname>Greenberg</surname> <given-names>E. P.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title><italic>Pseudomonas aeruginosa</italic> quorum sensing</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>1386</volume>, <fpage>95</fpage>&#x2013;<lpage>115</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-3-031-08491-1_4</pub-id>, PMID: <pub-id pub-id-type="pmid">36258070</pub-id>
</mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mitchell</surname> <given-names>P.</given-names></name>
</person-group> (<year>2011</year>). 
<article-title>Chemiosmotic coupling in oxidative and photosynthetic phosphorylation</article-title>. <source>Biochim. Biophys. Acta (BBA)  Bioenerget. Special Sect.: Peter Mitchell  50th Anniversary Chemiosmotic Theory</source> <volume>1807</volume>, <fpage>1507</fpage>&#x2013;<lpage>1538</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbabio.2011.09.018</pub-id>, PMID: <pub-id pub-id-type="pmid">22082452</pub-id>
</mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Moradali</surname> <given-names>M. F.</given-names></name>
<name><surname>Ghods</surname> <given-names>S.</given-names></name>
<name><surname>Rehm</surname> <given-names>B. H. A.</given-names></name>
</person-group> (<year>2017</year>). 
<article-title>Pseudomonas aeruginosa lifestyle: A paradigm for adaptation, survival, and persistence</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>7</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2017.00039</pub-id>, PMID: <pub-id pub-id-type="pmid">28261568</pub-id>
</mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Murray</surname> <given-names>C. J. L.</given-names></name>
<name><surname>Ikuta</surname> <given-names>K. S.</given-names></name>
<name><surname>Sharara</surname> <given-names>F.</given-names></name>
<name><surname>Swetschinski</surname> <given-names>L.</given-names></name>
<name><surname>Robles Aguilar</surname> <given-names>G.</given-names></name>
<name><surname>Gray</surname> <given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2022</year>). 
<article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title>. <source>Lancet</source> <volume>399</volume>, <fpage>629</fpage>&#x2013;<lpage>655</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id>, PMID: <pub-id pub-id-type="pmid">35065702</pub-id>
</mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Narten</surname> <given-names>M.</given-names></name>
<name><surname>Rosin</surname> <given-names>N.</given-names></name>
<name><surname>Schobert</surname> <given-names>M.</given-names></name>
<name><surname>Tielen</surname> <given-names>P.</given-names></name>
</person-group> (<year>2012</year>). 
<article-title>Susceptibility of <italic>Pseudomonas aeruginosa</italic> urinary tract isolates and influence of urinary tract conditions on antibiotic tolerance</article-title>. <source>Curr. Microbiol.</source> <volume>64</volume>, <fpage>7</fpage>&#x2013;<lpage>16</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00284-011-0026-y</pub-id>, PMID: <pub-id pub-id-type="pmid">21984270</pub-id>
</mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Newman</surname> <given-names>J.</given-names></name>
<name><surname>Floyd</surname> <given-names>R.</given-names></name>
<name><surname>Fothergill</surname> <given-names>J.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Invasion and diversity in <italic>Pseudomonas aeruginosa</italic> urinary tract infections</article-title>. <source>J. Med. Microbiol.</source> <volume>71</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1099/jmm.0.001458</pub-id>, PMID: <pub-id pub-id-type="pmid">35275806</pub-id>
</mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nickerson</surname> <given-names>R.</given-names></name>
<name><surname>Thornton</surname> <given-names>C. S.</given-names></name>
<name><surname>Johnston</surname> <given-names>B.</given-names></name>
<name><surname>Lee</surname> <given-names>A. H. Y.</given-names></name>
<name><surname>Cheng</surname> <given-names>Z.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title><italic>Pseudomonas aeruginosa</italic> in chronic lung disease: untangling the dysregulated host immune response</article-title>. <source>Front. Immunol.</source> <volume>15</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1405376</pub-id>, PMID: <pub-id pub-id-type="pmid">39015565</pub-id>
</mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Novo</surname> <given-names>D.</given-names></name>
<name><surname>Perlmutter</surname> <given-names>N. G.</given-names></name>
<name><surname>Hunt</surname> <given-names>R. H.</given-names></name>
<name><surname>Shapiro</surname> <given-names>H. M.</given-names></name>
</person-group> (<year>1999</year>). 
<article-title>Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique</article-title>. <source>Cytometry</source> <volume>35</volume>, <fpage>55</fpage>&#x2013;<lpage>63</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/(SICI)1097-0320(19990101)35:1%253C55::AID-CYTO8%253E3.0.CO;2-2</pub-id>, PMID: <pub-id pub-id-type="pmid">10554181</pub-id>
</mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>O&#x2019;Toole</surname> <given-names>G. A.</given-names></name>
</person-group> (<year>2011</year>). 
<article-title>Microtiter dish biofilm formation assay</article-title>. <source>J. Vis. Exp.</source> <volume>47</volume>, <fpage>2437</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3791/2437</pub-id>, PMID: <pub-id pub-id-type="pmid">21307833</pub-id>
</mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ojoo</surname> <given-names>J.</given-names></name>
<name><surname>Mulrennan</surname> <given-names>S.</given-names></name>
<name><surname>Kastelik</surname> <given-names>J.</given-names></name>
<name><surname>Morice</surname> <given-names>A.</given-names></name>
<name><surname>Redington</surname> <given-names>A.</given-names></name>
</person-group> (<year>2005</year>). 
<article-title>Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis</article-title>. <source>Thorax</source> <volume>60</volume>, <fpage>22</fpage>&#x2013;<lpage>26</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/thx.2003.017327</pub-id>, PMID: <pub-id pub-id-type="pmid">15618578</pub-id>
</mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pagacz</surname> <given-names>J.</given-names></name>
<name><surname>Broniec</surname> <given-names>A.</given-names></name>
<name><surname>Wolska</surname> <given-names>M.</given-names></name>
<name><surname>Osyczka</surname> <given-names>A.</given-names></name>
<name><surname>Borek</surname> <given-names>A.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>ROS signaling capacity of cytochrome <italic>bc</italic>1: Opposing effects of adaptive and pathogenic mitochondrial mutations</article-title>. <source>Free Radical Biol. Med.</source> <volume>163</volume>, <fpage>243</fpage>&#x2013;<lpage>254</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.12.019</pub-id>, PMID: <pub-id pub-id-type="pmid">33352219</pub-id>
</mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pan</surname> <given-names>X.</given-names></name>
<name><surname>Dong</surname> <given-names>Y.</given-names></name>
<name><surname>Fan</surname> <given-names>Z.</given-names></name>
<name><surname>Liu</surname> <given-names>C.</given-names></name>
<name><surname>Xia</surname> <given-names>B.</given-names></name>
<name><surname>Shi</surname> <given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2017</year>). 
<article-title><italic>In vivo</italic> Host Environment Alters <italic>Pseudomonas aeruginosa</italic> Susceptibility to Aminoglycoside Antibiotics</article-title>. <source>Front. Cell Infect. Microbiol.</source> <volume>7</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2017.00083</pub-id>, PMID: <pub-id pub-id-type="pmid">28352614</pub-id>
</mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Phillips</surname> <given-names>R. M.</given-names></name>
<name><surname>Six</surname> <given-names>D. A.</given-names></name>
<name><surname>Dennis</surname> <given-names>E. A.</given-names></name>
<name><surname>Ghosh</surname> <given-names>P.</given-names></name>
</person-group> (<year>2003</year>). 
<article-title><italic>In vivo</italic> phospholipase activity of the <italic>Pseudomonas aeruginosa</italic> cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors *</article-title>. <source>J. Biol. Chem.</source> <volume>278</volume>, <fpage>41326</fpage>&#x2013;<lpage>41332</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M302472200</pub-id>, PMID: <pub-id pub-id-type="pmid">12915403</pub-id>
</mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Potvin</surname> <given-names>E.</given-names></name>
<name><surname>Sanschagrin</surname> <given-names>F.</given-names></name>
<name><surname>Levesque</surname> <given-names>R. C.</given-names></name>
</person-group> (<year>2008</year>). 
<article-title>Sigma factors in <italic>Pseudomonas aeruginosa</italic></article-title>. <source>FEMS Microbiol. Rev.</source> <volume>32</volume>, <fpage>38</fpage>&#x2013;<lpage>55</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00092.x</pub-id>, PMID: <pub-id pub-id-type="pmid">18070067</pub-id>
</mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Qin</surname> <given-names>S.</given-names></name>
<name><surname>Xiao</surname> <given-names>W.</given-names></name>
<name><surname>Zhou</surname> <given-names>C.</given-names></name>
<name><surname>Pu</surname> <given-names>Q.</given-names></name>
<name><surname>Deng</surname> <given-names>X.</given-names></name>
<name><surname>Lan</surname> <given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>2022</year>). 
<article-title><italic>Pseudomonas aeruginosa</italic>: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics</article-title>. <source>Sig. Transduct. Target. Ther.</source> <volume>7</volume>, <fpage>199</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41392-022-01056-1</pub-id>, PMID: <pub-id pub-id-type="pmid">35752612</pub-id>
</mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Raba</surname> <given-names>D. A.</given-names></name>
<name><surname>Rosas-Lemus</surname> <given-names>M.</given-names></name>
<name><surname>Menzer</surname> <given-names>W. M.</given-names></name>
<name><surname>Li</surname> <given-names>C.</given-names></name>
<name><surname>Fang</surname> <given-names>X.</given-names></name>
<name><surname>Liang</surname> <given-names>P.</given-names></name>
<etal/>
</person-group>. (<year>2018</year>). 
<article-title>Characterization of the <italic>Pseudomonas aeruginosa</italic> NQR complex, a bacterial proton pump with roles in autopoisoning resistance</article-title>. <source>J. Biol. Chem.</source> <volume>293</volume>, <fpage>15664</fpage>&#x2013;<lpage>15677</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.RA118.003194</pub-id>, PMID: <pub-id pub-id-type="pmid">30135204</pub-id>
</mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Reynolds</surname> <given-names>D.</given-names></name>
<name><surname>Kollef</surname> <given-names>M.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>The epidemiology and pathogenesis and treatment of <italic>Pseudomonas aeruginosa</italic> infections: an update</article-title>. <source>Drugs</source> <volume>81</volume>, <fpage>2117</fpage>&#x2013;<lpage>2131</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s40265-021-01635-6</pub-id>, PMID: <pub-id pub-id-type="pmid">34743315</pub-id>
</mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenfeld</surname> <given-names>M.</given-names></name>
<name><surname>Gibson</surname> <given-names>R. L.</given-names></name>
<name><surname>McNamara</surname> <given-names>S.</given-names></name>
<name><surname>Emerson</surname> <given-names>J.</given-names></name>
<name><surname>Burns</surname> <given-names>J. L.</given-names></name>
<name><surname>Castile</surname> <given-names>R.</given-names></name>
<etal/>
</person-group>. (<year>2001</year>). 
<article-title>Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis</article-title>. <source>Pediatr. Pulmonol.</source> <volume>32</volume>, <fpage>356</fpage>&#x2013;<lpage>366</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ppul.1144</pub-id>, PMID: <pub-id pub-id-type="pmid">11596160</pub-id>
</mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ruhluel</surname> <given-names>D.</given-names></name>
<name><surname>O&#x2019;Brien</surname> <given-names>S.</given-names></name>
<name><surname>Fothergill</surname> <given-names>J. L.</given-names></name>
<name><surname>Neill</surname> <given-names>D. R.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Development of liquid culture media mimicking the conditions of sinuses and lungs in cystic fibrosis and health</article-title>. <source>F1000Res</source> <volume>11</volume>, <fpage>1007</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.12688/f1000research.125074.2</pub-id>, PMID: <pub-id pub-id-type="pmid">36519007</pub-id>
</mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sato</surname> <given-names>H.</given-names></name>
<name><surname>Frank</surname> <given-names>D. W.</given-names></name>
<name><surname>Hillard</surname> <given-names>C. J.</given-names></name>
<name><surname>Feix</surname> <given-names>J. B.</given-names></name>
<name><surname>Pankhaniya</surname> <given-names>R. R.</given-names></name>
<name><surname>Moriyama</surname> <given-names>K.</given-names></name>
<etal/>
</person-group>. (<year>2003</year>). 
<article-title>The mechanism of action of the <italic>Pseudomonas aeruginosa</italic>-encoded type III cytotoxin, ExoU</article-title>. <source>EMBO J.</source> <volume>22</volume>, <fpage>2959</fpage>&#x2013;<lpage>2969</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/emboj/cdg290</pub-id>, PMID: <pub-id pub-id-type="pmid">12805211</pub-id>
</mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Savli</surname> <given-names>H.</given-names></name>
<name><surname>Karadenizli</surname> <given-names>A.</given-names></name>
<name><surname>Kolayli</surname> <given-names>F.</given-names></name>
<name><surname>Gundes</surname> <given-names>S.</given-names></name>
<name><surname>Ozbek</surname> <given-names>U.</given-names></name>
<name><surname>Vahaboglu</surname> <given-names>H.</given-names></name>
</person-group> (<year>2003</year>). 
<article-title>Expression stability of six housekeeping genes: A proposal for resistance gene quantification studies of <italic>Pseudomonas aeruginosa</italic> by real-time quantitative RT-PCR</article-title>. <source>J. Med. Microbiol.</source> <volume>52</volume>, <fpage>403</fpage>&#x2013;<lpage>408</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1099/jmm.0.05132-0</pub-id>, PMID: <pub-id pub-id-type="pmid">12721316</pub-id>
</mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Seaver</surname> <given-names>L. C.</given-names></name>
<name><surname>Imlay</surname> <given-names>J. A.</given-names></name>
</person-group> (<year>2004</year>). 
<article-title>Are respiratory enzymes the primary sources of intracellular hydrogen peroxide</article-title>? <source>J. Biol. Chem.</source> <volume>279</volume>, <fpage>48742</fpage>&#x2013;<lpage>48750</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M408754200</pub-id>, PMID: <pub-id pub-id-type="pmid">15361522</pub-id>
</mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shen</surname> <given-names>L.</given-names></name>
<name><surname>Gao</surname> <given-names>L.</given-names></name>
<name><surname>Yang</surname> <given-names>M.</given-names></name>
<name><surname>Zhang</surname> <given-names>J.</given-names></name>
<name><surname>Wang</surname> <given-names>Y.</given-names></name>
<name><surname>Feng</surname> <given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2021</year>). 
<article-title>Deletion of the PA4427-PA4431 operon of <italic>Pseudomonas aeruginosa</italic> PAO1 increased antibiotics resistance and reduced virulence and pathogenicity by affecting quorum sensing and iron uptake</article-title>. <source>Microorganisms</source> <volume>9</volume>, <elocation-id>1065</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/microorganisms9051065</pub-id>, PMID: <pub-id pub-id-type="pmid">34069209</pub-id>
</mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Silistre</surname> <given-names>H.</given-names></name>
<name><surname>Raoux-Barbot</surname> <given-names>D.</given-names></name>
<name><surname>Mancinelli</surname> <given-names>F.</given-names></name>
<name><surname>Sangouard</surname> <given-names>F.</given-names></name>
<name><surname>Dupin</surname> <given-names>A.</given-names></name>
<name><surname>Belyy</surname> <given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2021</year>). 
<article-title>Prevalence of ExoY activity in <italic>Pseudomonas aeruginosa</italic> reference panel strains and impact on cytotoxicity in epithelial cells</article-title>. <source>Front. Microbiol.</source> <volume>12</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmicb.2021.666097</pub-id>, PMID: <pub-id pub-id-type="pmid">34675890</pub-id>
</mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Six</surname> <given-names>A.</given-names></name>
<name><surname>Mosbahi</surname> <given-names>K.</given-names></name>
<name><surname>Barge</surname> <given-names>M.</given-names></name>
<name><surname>Kleanthous</surname> <given-names>C.</given-names></name>
<name><surname>Evans</surname> <given-names>T.</given-names></name>
<name><surname>Walker</surname> <given-names>D.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>Pyocin efficacy in a murine model of <italic>Pseudomonas aeruginosa</italic> sepsis</article-title>. <source>J. Antimicrob. Chemother.</source> <volume>76</volume>, <fpage>2317</fpage>&#x2013;<lpage>2324</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/jac/dkab199</pub-id>, PMID: <pub-id pub-id-type="pmid">34142136</pub-id>
</mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Soares</surname> <given-names>A.</given-names></name>
<name><surname>Alexandre</surname> <given-names>K.</given-names></name>
<name><surname>Etienne</surname> <given-names>M.</given-names></name>
</person-group> (<year>2020</year>). 
<article-title>Tolerance and persistence of <italic>Pseudomonas aeruginosa</italic> in biofilms exposed to antibiotics: molecular mechanisms, antibiotic strategies and therapeutic perspectives</article-title>. <source>Front. Microbiol.</source> <volume>11</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmicb.2020.02057</pub-id>, PMID: <pub-id pub-id-type="pmid">32973737</pub-id>
</mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Soh</surname> <given-names>E. Y.-C.</given-names></name>
<name><surname>Smith</surname> <given-names>F.</given-names></name>
<name><surname>Gimenez</surname> <given-names>M. R.</given-names></name>
<name><surname>Yang</surname> <given-names>L.</given-names></name>
<name><surname>Vejborg</surname> <given-names>R. M.</given-names></name>
<name><surname>Fletcher</surname> <given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2021</year>). 
<article-title>Disruption of the <italic>Pseudomonas aeruginosa</italic> Tat system perturbs PQS-dependent quorum sensing and biofilm maturation through lack of the Rieske cytochrome bc1 sub-unit</article-title>. <source>PloS Pathog.</source> <volume>17</volume>, <fpage>e1009425</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1009425</pub-id>, PMID: <pub-id pub-id-type="pmid">34460871</pub-id>
</mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Srivastav</surname> <given-names>S.</given-names></name>
<name><surname>Biswas</surname> <given-names>A.</given-names></name>
<name><surname>Anand</surname> <given-names>A.</given-names></name>
</person-group> (<year>2025</year>). 
<article-title>Interplay of niche and respiratory network in shaping bacterial colonization</article-title>. <source>J. Biol. Chem.</source> <volume>301</volume>, <elocation-id>108052</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jbc.2024.108052</pub-id>, PMID: <pub-id pub-id-type="pmid">39662826</pub-id>
</mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Stover</surname> <given-names>C. K.</given-names></name>
<name><surname>Pham</surname> <given-names>X. Q.</given-names></name>
<name><surname>Erwin</surname> <given-names>A. L.</given-names></name>
<name><surname>Mizoguchi</surname> <given-names>S. D.</given-names></name>
<name><surname>Warrener</surname> <given-names>P.</given-names></name>
<name><surname>Hickey</surname> <given-names>M. J.</given-names></name>
<etal/>
</person-group>. (<year>2000</year>). 
<article-title>Complete genome sequence of <italic>Pseudomonas aeruginosa</italic> PAO1, an opportunistic pathogen</article-title>. <source>Nature</source> <volume>406</volume>, <fpage>959</fpage>&#x2013;<lpage>964</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/35023079</pub-id>, PMID: <pub-id pub-id-type="pmid">10984043</pub-id>
</mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Symersky</surname> <given-names>J.</given-names></name>
<name><surname>Osowski</surname> <given-names>D.</given-names></name>
<name><surname>Walters</surname> <given-names>D. E.</given-names></name>
<name><surname>Mueller</surname> <given-names>D. M.</given-names></name>
</person-group> (<year>2012</year>). 
<article-title>Oligomycin frames a common drug-binding site in the ATP synthase</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>109</volume>, <fpage>13961</fpage>&#x2013;<lpage>13965</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1207912109</pub-id>, PMID: <pub-id pub-id-type="pmid">22869738</pub-id>
</mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Torres</surname> <given-names>A.</given-names></name>
<name><surname>Kasturiarachi</surname> <given-names>N.</given-names></name>
<name><surname>DuPont</surname> <given-names>M.</given-names></name>
<name><surname>Cooper</surname> <given-names>V. S.</given-names></name>
<name><surname>Bomberger</surname> <given-names>J.</given-names></name>
<name><surname>Zemke</surname> <given-names>A.</given-names></name>
</person-group> (<year>2019</year>). 
<article-title>NADH dehydrogenases in <italic>Pseudomonas aeruginosa</italic> growth and virulence</article-title>. <source>Front. Microbiol</source>. <volume>10</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmicb.2019.00075</pub-id>, PMID: <pub-id pub-id-type="pmid">30804898</pub-id>
</mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Untergasser</surname> <given-names>A.</given-names></name>
<name><surname>Cutcutache</surname> <given-names>I.</given-names></name>
<name><surname>Koressaar</surname> <given-names>T.</given-names></name>
<name><surname>Ye</surname> <given-names>J.</given-names></name>
<name><surname>Faircloth</surname> <given-names>B. C.</given-names></name>
<name><surname>Remm</surname> <given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2012</year>). 
<article-title>Primer3--new capabilities and interfaces</article-title>. <source>Nucleic Acids Res.</source> <volume>40</volume>, <fpage>e115</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nar/gks596</pub-id>, PMID: <pub-id pub-id-type="pmid">22730293</pub-id>
</mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Walker</surname> <given-names>D. J.</given-names></name>
<name><surname>Wakefield</surname> <given-names>A. E.</given-names></name>
<name><surname>Dohn</surname> <given-names>M. N.</given-names></name>
<name><surname>Miller</surname> <given-names>R. F.</given-names></name>
<name><surname>Baughman</surname> <given-names>R. P.</given-names></name>
<name><surname>Hossler</surname> <given-names>P. A.</given-names></name>
<etal/>
</person-group>. (<year>1998</year>). 
<article-title>Sequence Polymorphisms in the <italic>Pneumocystis carinii</italic> Cytochrome b Gene and Their Association with Atovaquone Prophylaxis Failure</article-title>. <source>J. Infect. Dis.</source> <volume>178</volume>, <fpage>1767</fpage>&#x2013;<lpage>1775</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1086/314509</pub-id>, PMID: <pub-id pub-id-type="pmid">9815231</pub-id>
</mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wiehlmann</surname> <given-names>L.</given-names></name>
<name><surname>Wagner</surname> <given-names>G.</given-names></name>
<name><surname>Cramer</surname> <given-names>N.</given-names></name>
<name><surname>Siebert</surname> <given-names>B.</given-names></name>
<name><surname>Gudowius</surname> <given-names>P.</given-names></name>
<name><surname>Morales</surname> <given-names>G.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>). 
<article-title>Population structure of <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>104</volume>, <fpage>8101</fpage>&#x2013;<lpage>8106</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0609213104</pub-id>, PMID: <pub-id pub-id-type="pmid">17468398</pub-id>
</mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname> <given-names>H. D.</given-names></name>
<name><surname>Zlosnik</surname> <given-names>J. E. A.</given-names></name>
<name><surname>Ryall</surname> <given-names>B.</given-names></name>
</person-group> (<year>2007</year>). 
<article-title>Oxygen, cyanide and energy generation in the cystic fibrosis pathogen <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Adv. Microb. Physiol.</source> <volume>52</volume>, <fpage>1</fpage>&#x2013;<lpage>71</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0065-2911(06)52001-6</pub-id>, PMID: <pub-id pub-id-type="pmid">17027370</pub-id>
</mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yagi</surname> <given-names>T.</given-names></name>
</person-group> (<year>1991</year>). 
<article-title>Bacterial NADH-quinone oxidoreductases</article-title>. <source>J. Bioenerg. Biomembr.</source> <volume>23</volume>, <fpage>211</fpage>&#x2013;<lpage>225</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/BF00762218</pub-id>, PMID: <pub-id pub-id-type="pmid">2050655</pub-id>
</mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zambrano</surname> <given-names>M. M.</given-names></name>
<name><surname>Kolter</surname> <given-names>R.</given-names></name>
</person-group> (<year>1993</year>). 
<article-title><italic>Escherichia coli</italic> mutants lacking NADH dehydrogenase I have a competitive disadvantage in stationary phase</article-title>. <source>J. Bacteriol.</source> <volume>175</volume>, <fpage>5642</fpage>&#x2013;<lpage>5647</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/jb.175.17.5642-5647.1993</pub-id>, PMID: <pub-id pub-id-type="pmid">8366049</pub-id>
</mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname> <given-names>W.</given-names></name>
<name><surname>Bertsova</surname> <given-names>Y. V.</given-names></name>
<name><surname>Feng</surname> <given-names>B.</given-names></name>
<name><surname>Tsatsos</surname> <given-names>P.</given-names></name>
<name><surname>Verkhovskaya</surname> <given-names>M. L.</given-names></name>
<name><surname>Gennis</surname> <given-names>R. B.</given-names></name>
<etal/>
</person-group>. (<year>1999</year>). 
<article-title>Sequencing and preliminary characterization of the Na+-translocating NADH: ubiquinone oxidoreductase from <italic>Vibrio harveyi</italic></article-title>. <source>Biochemistry</source> <volume>38</volume>, <fpage>16246</fpage>&#x2013;<lpage>16252</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/bi991664s</pub-id>, PMID: <pub-id pub-id-type="pmid">10587447</pub-id>
</mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zickermann</surname> <given-names>V.</given-names></name>
<name><surname>Kurki</surname> <given-names>S.</given-names></name>
<name><surname>Kervinen</surname> <given-names>M.</given-names></name>
<name><surname>Hassinen</surname> <given-names>I.</given-names></name>
<name><surname>Finel</surname> <given-names>M.</given-names></name>
</person-group> (<year>2000</year>). 
<article-title>The NADH oxidation domain of complex I: do bacterial and mitochondrial enzymes catalyze ferricyanide reduction similarly</article-title>? <source>Biochim. Biophys. Acta</source> <volume>1459</volume>, <fpage>61</fpage>&#x2013;<lpage>68</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0005-2728(00)00113-4</pub-id>, PMID: <pub-id pub-id-type="pmid">10924899</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1214617">Anna K&#x119;dziora</ext-link>, University of Wroc&#x142;aw, Poland</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2551479">Eva Krzy&#x17c;ewska-Dudek</ext-link>, Polish Academy of Sciences, Poland</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3314975">Ivanka Karad&#x17e;i&#x107;</ext-link>, University of Belgrade, Serbia</p></fn>
</fn-group>
</back>
</article>